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ABSTRACT
Platelet activation initiates an upsurge in 18:2 and 20:4 lysophosphatidic acid
(LPA) production. The biochemical pathway responsible for LPA production during
blood clotting is not fully understood. We have purified a phospholipase A1 (PLA1) from
thrombin-activated human platelets using sequential chromatographic steps followed by
fluorophosphonate-biotin affinity labeling and proteomics. We identified acyl-protein
thioesterase 1 (aka. lysophospholipase A1, accession code O75608) as a novel PLA1.
Addition of this recombinant PLA1 significantly increased the production of
sn-2-esterified polyunsaturated LPCs and the corresponding LPAs in plasma. We next
examined the regioisomeric preference of lysophospholipase D/autotaxin (ATX), which
is the subsequent step in LPA production. To prevent acylmigration regioisomers of
oleyl-sn-glycero-3-phosphocholine (LPAF) were synthesized. ATX preferred the sn-1
over the sn-2 regioisomer of LPAF. We propose the following LPA production pathway
in blood: 1) Activated platelets secrete PLA1. 2) PLA1 generates a pool of sn-2
lysophospholipids. 3) These newly generated sn-2 lysophospholipids undergo acyl
migration to yield sn-1 lysophospholipids, which are the preferred substrates of ATX. 4)
ATX cleaves the sn-1 lysophospholipids to generate sn-1 LPA species predominant with
18:2 and 20:4 fatty acids.
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CHAPTER 1. GENERAL INTRODUCTION
1.1 PHOSPHOLIPID PRODUCTION
1.1.1

Lysophosphatidic Acid

Lysophosphatidic acid (LPA; Figure 1.1) has been studied by many chemists,
biochemists, biologists, and physicians since it was first identified in 1957 as the active
ingredient of a smooth muscle-stimulating substance, Darmstoff (Vogt, 1957a; b). Many
advances have been made throughout the years in determining the production,
breakdown, and receptors for LPA, but many aspects of LPA are still unknown.
Various species of LPA, dominated by 16-, 18-, and 20- carbon long acyl chains,
are produced in cells as an intermediate to lipid synthesis and extracellularly in many
biological fluids. The different species of LPA provides a unique opportunity for
specificity within the receptors. For example, most LPA GPCRs prefer unsaturated
species.
1.1.2 The GPAT Pathway of LPA Synthesis
LPA is generated via many different mechanisms. One pathway of LPA
production is through glycerophosphate acyltransferase (GPAT). GPAT acylates glycerol
3-phosphate to generate LPA in the endoplasmic reticulum and mitochondria (Das and
Hajra, 1984; Aoki, 2004; Gendaszewska-Darmach, 2008). This LPA may be quickly
broken down into phosphatidic acid (PA) by monoacylglycerolphosphate acyltransferase,
but some of this LPA may contribute to the intracellular LPA.
1.1.3 LPA Generation by MAGK
A lipid kinase involved in the pathway of LPA production was identified in 1962
(Pieringer and Hokin, 1962). This kinase was later identified as monoacylglycerol kinase
and the phosphorylation of monoacylglycerol by this enzyme within the plasma
membrane contributes to the production of LPA (Bektas et al., 2005).
1.1.4 LPA Synthesis from PA
LPA is also generated via the hydrolysis of fatty acids at either the sn-1 position
or the sn-2 position of PA by (phospholipase A1) PLA1 or (phospholipase A2) PLA2
enzymes respectively. PA-specific PLA1 and PLA2 enzymes have been reported in
human (Billah et al., 1980; Sano et al., 2002; Sonoda et al., 2002), horse (Billah et al.,
1981), and pig (Inoue and Okuyama, 1984) platelets. However this is shown to only
1

Figure 1.1 Chemical structure of sn-1 Lysophosphatidic acid 18:1.
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produce a small portion (10%) of LPA detected in serum (Gaits et al., 1997; Aoki et al.,
2002b; Cummings et al., 2002; Sano et al., 2002; Aoki, 2004).
1.1.5 LPA Production via PLA2 Hydrolysis
LPA is also produced by a secretory or type II phospholipase A2 (sPLA2)
(Fourcade et al., 1995). LPA has also been shown to be generated in a spatially regulated
fashion by the Ca2+-independent PLA2 at the leading edge of migrating monocytes
(Carnevale and Cathcart, 2001; Mishra et al., 2008).
1.1.6 LPA Production via PS-PLA1
Another pathway of LPA production involves a phosphatidylserine (PS)-specific
phospholipase A1 (PS-PLA1) that can generate lysophosphatidylserine (LPS) This LPS is
then converted into LPA by intracellular phospholipase D action (Nagai et al., 1999,
Aoki et al., 2002a).
1.1.7 LPA Production during LDL Oxidation
Low density lipoprotein (LDL) often gets oxidized which produces many lipid
constituents. Mildly oxidized low density lipoprotein (moxLDL) induces platelet and
endothelial cell shape changes (Siess et al., 1999). The pro-thrombotic and proatherogenic properties of the moxLDL are due to LPA.
1.1.8 LPA Generation by Phospholipase and Lysophospholipase D Cleavage
Lysophospholipase D (LPLD) activity is present in most biological fluids. LPLDmediated production of LPA was first projected in the early 1980’s in rat plasma
(Tokumura et al., 1986). LPLD acts on LPLs by removing the headgroup from LPLs
resulting in LPA. This enzymatic pathway for LPA production will be described in
greater detail in a subsequent section.
1.1.9 LPA Upregulation during Blood Coagulation
Although many pathways are responsible for LPA production, perhaps the most
significant pathway is a multi-step process linked to activation of platelets (Mauco et al.,
1978; Schumacher et al., 1979; Eichholtz et al., 1993; Gaits et al., 1997; Sano et al.,
2002; Aoki et al., 2008). This multistep mechanism involves the release of unidentified
PLA1 and/or PLA2 enzymes from activated platelets generating a new pool of
lysophospholipids (LPLs), which in turn are cleaved by a lysophospholipase D also
known as autotaxin (ATX) (Tokumura et al., 2002; Umezu-Goto et al., 2002).
3

Under normal circumstances, LPA levels in plasma are less than 100nM and the
rank order of species is 18:2 > 18:1 > 18:0 > 16:0 > 20:4. These levels increase during
blood coagulation to reach up to 10 µM and show an increase in the unsaturated species
(Baker et al., 2001; Sano et al., 2002; Watanabe et al., 2007; Hosogaya et al., 2008). The
rank order of LPA species in serum is 20:4 > 18:2 > 16:0 > 18:1 > 18:0 (Sano et al.,
2002).
The mechanism behind the increase in LPA upon blood coagulation is still
unknown. It was first proposed that platelets were the source of high levels of LPA in
serum. However, the amount of LPA released from activated platelets is insufficient to
explain the large amount of LPA in serum. Tigyi, et. al. first showed that platelets secrete
enzymes that act on plasma phospholipids that in turn generate LPA, which has been
confirmed by other groups (Baker et al., 2001; Aoki et al., 2002a). Linoleoyl- (18:2) and
arachidonoyl (20:4) species make up 84% of the LPA found in serum (Baker et al.,
2001). The difference in the abundance of molecular species between serum and plasma
leads to the hypothesis that LPA present in serum is generated via a pathway distinct
from that of LPA present in plasma. Furthermore, the dominating abundance of the
arachidonoyl (20:4) and linoleoyl (18:2) species of LPA in serum suggests that these
LPAs are derived through a PLA1 enzymatic mechanism because these two lipids are
esterified to the sn-2 position of plasma lipids.
Preliminary data support this hypothesis of LPA production. It has been shown
that the incubation of NBD fluorescent labeled phosphatidylcholine (PC),
phosphatidylserine (PS) and phosphatidylethanolamine (PE) with supernatant from
thrombin stimulated platelets are converted into lysophospholipids by PLA1 activity.
When spiked into serum or plasma these lysophospholipids are then converted into LPA
(Baker et al., 2001). Previous studies have shown that lysophospholipase D (LPLD) is
capable of generating LPA in plasma by preferentially acting on unsaturated
lysophosphatidylcholine (Tokumura et al., 1998). This suggests that thrombin activated
platelets produce LPA through the cleavage of phospholipids to lysophospholipids by
platelet derived PLA1 and to a much lesser extent PLA2 and then LPC is further cleaved
by LPLD into LPA. It is well established that fatty acids esterified to the sn-2 position
are unstable and undergo acyl migration in minutes to yield a more stable sn-1
regioisomer (Pluckthun and Dennis, 1982; Sano et al., 2002). Thus, we predict that the
arachidonoyl- and linoleoyl-LPA are first derived as a sn-2 regioisomers from the
corresponding lysophospholipids and then rapidly undergo acyl migration to yield the sn1 isomers that are stable and have been detected in serum.
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1.2 LPA DEGRADATION
1.2.1

LPA Degradation by Phosphatases

Lysophospholipids are dephosphorylated by the lipid phosphate
phosphohydrolase family (LPP) (Brindley and Waggoner, 1998). There are four known
isoforms that have been cloned and characterized in mammals, LPP1/PAP-2a/PAP2α1(Kai et al., 1997), LPP1a/PAP-2α2 (Leung et al., 1998), LPP2/PAP-2c/PAP-2ᵧ
(Roberts et al., 1998), and LPP3/PAP-2b/PAP-2β (Kai et al., 1997). Each member of the
LPP family exhibits selectivity for various phospholipid substrates. The LPP1 family
prefers LPA as a substrate followed by PA, sphingosine 1-phosphate (S1P), and ceramide
1-phosphate (C1P) (Waggoner et al., 1996). LPP2/PAP-2c/PAP-2ᵧ prefers PA, then C1P,
LPA, and S1P (Roberts et al., 1998). Lastly, LPP3/PAP-2b/PAP-2β converts PA and
LPA with the same efficiency and to a much lesser extent will convert S1P and C1P.
LPA degradation occurs by the removal of the phosphate group by phosphatases to yield
monoacylglycerol. LPA is also degraded by a nuclear LPA phosphohydrolase which is
yet unidentified (Baker and Chang, 2000).
1.2.2

LPA Degradation by Lysophospholipases

LPA can also be degraded by the hydrolysis of the acyl group from the glycerol
backbone by lysophospholipase enzymes. Whereas many lysophospholipids prefer LPC
substrates over LPA, LPA has been reported in rabbit neuronal nuclei to act as a
competitive inhibitor of LPC lysophospholipase activity (Baker and Chang, 2000). It has
also been reported that LPA is a substrate of a distinct LPA lysophospholipase activity
(Baker and Chang, 2000).
A lysophospholipase with LPA lysophospholipase activity has been purified from
rat brain (Thompson and Clark, 1994). It is an 80kDa enzyme and prefers 1-oleoyl and 1stereoyl LPA species followed by 1-palmitoyl and 1-myristoyl LPA. The purified enzyme
does not hydrolyze LPE, LPI, or LPS (Thompson and Clark, 1994).
1.2.3

LPA Degradation by Acyltransferases

1-acylglycerol 3-phosphate acyltransferase (AGPAT), also known as
lysophosphatidic acid acyltransferases (LPAAT) catalyzes the transfer of an acyl group
from acyl-CaA to LPA to form PA. Five members of the LPAAT family have been
identified: LPAATα/1-AGPAT 1 (Kume and Shimizu, 1997; Aguado and Campbell,
1998), LPAATβ/1-AGPAT 2 (Aguado and Campbell, 1998), LPAATγ/1-AGPAT 3,
LPAATδ/1-AGPAT 4, and LPAATε/1-AGPAT 5. LPAATα and LPAATβ have a much
higher catalytic activity than the other family members (Leung, 2001) and therefore
contribute most of the LPAAT activity in cells. LPAATα shows a marked preference for
LPA over the other members of the family. LPAATα is found consistently in most
5

tissues, however LPAATβ is differentially expressed and elevated in many tumor tissues
relating the overproduction of PA to many cancer types.
It is important to note that LPAAT esterifies the sn-2 position of LPA to produce
PA using acyl-CoAs as substrates and has been shown to prefer arachidonloyl (20:4)CoA (Yuki et al., 2009; Koeberle et al., 2010). This generates unsaturated fatty acids in
the sn-2 position of PA, which can then receive a choline or serine headgroup and
become a prime substrate for a PLA1/2 enzyme.
1.3 LPA RECEPTOR AND SIGNALING
1.3.1

Plasma Membrane Receptors

LPA is a phospholipid mediator that acts through multiple targets that include G
protein-coupled receptors (GPCRs) and a nuclear receptor, peroxisome proliferatoractivated receptor gamma (PPARgamma) as well as enzymes. To date there are eight
known LPA-specific receptors (LPA1-8). LPA1-3 are members of the endothelial
differentiation gene (EDG) family (Tigyi and Parrill, 2003; Choi et al., 2008; Mutoh and
Chun, 2008; Rivera and Chun, 2008; Ishii et al., 2009; Noguchi et al., 2009; Peyruchaud,
2009; Tigyi, 2010). These three members share 45-56% overall amino acid identity. The
transmembrane domains of the human LPA EDG family receptors share 81% homology
with one another, however only 6% is conserved within the C-terminal tail. There are
also five S1P-specific receptors that are included in this gene cluster of GPCRs: S1P1,
S1P2, S1P3, S1P4, and S1P5.
LPA1/EDG2 mRNA is highly abundant in brain tissue, and to a lesser extent in
heart tissue, the gastrointestinal tract, and the reproductive system (An et al., 1997; Tigyi,
2010). It has also been found in the rabbit cornea (Wang et al., 2002). LPA1/EDG2 elicits
its actions through the activation of heterotrimeric G proteins which results in the
inhibition of adenylyl cyclase (Hecht et al., 1996), DNA synthesis, Ca2+ signaling,
phospholipase C activation (An et al., 1998), activation of the serum response element
(Contos and Chun, 1998), and stimulation of Rho signaling (Fukushima et al., 1998).
LPA2 is found primarily in testis and leukocytes (An et al., 1998; Tigyi, 2010). It
is also found in embryonic and neonatal mouse brain tissue. It elicits its actions through
G protein pathways that mediate intracellular Ca2+ mobilization, which activates MAP
kinase and serum response element (An et al., 1998; Bandoh et al., 1999).
LPA3 mRNA is mainly expressed in the human heart, prostate, testis, pancreas
(Bandoh et al., 1999; Im et al., 2000), rat kidney and testis (Im et al., 2000), and rabbit
cornea (Wang et al., 2002). LPA3 is similar to LPA2 in that it activates the MAP kinase
pathway however; in addition, it also stimulates adenylyl cylclase (Bandoh et al., 1999).
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LPA4/p2y9/GPR23 (Noguchi et al., 2003; Yanagida et al., 2007), LPA5/GPR92
(Kotarsky et al., 2006; Lee et al., 2006; Williams et al., 2009; Yin et al., 2009),
LPA6/GPR87 (Tabata et al., 2007), LPA7/p2y5 (Pasternack et al., 2008; Shimomura et
al., 2008), and LPA8/p2y10 (Murakami et al., 2008) are more closely related to the
purinoreceptor cluster of GPCR and only share about 20% homology with the LPA EDG
family receptors.
LPA4/p2y9/GPR23 is found primarily in the ovary, uterus, and placenta (Ishii et
al., 2009). It has also been found in the brain and been shown to cause LPA-dependent
growth cone collapse and neurite retraction through G12/13-RhoA-Rho-associated kinase
(ROCK) activation (Lee et al., 2007). The ligand preference of LPA4/p2y9/GPR23 is
LPA 18:1>18:0>16:0>14:0>1-O-alkyl glycerophosphate>1-O-alkenyl glycerophosphate
(Noguchi et al., 2003).
LPA5/GPR92 is found in the heart, placenta, dorsal root ganglia, small intestine,
spleen, brain, B cells, intestinal CD8+ lymphocytes, and platelets (Kotarsky et al., 2006).
The ligand preference of LPA5/GPR92 is 1-O-alkyl glycerophosphate 18:1>1-O-alkyl
glycerophosphate 18:0>LPA 18:1>20:4=16:0=18:3>farnesyl monophosphate>farnesyl
diphosphate>LPA 18:0 (Noguchi et al., 2003).
LPA6/GPR87 is typically found in brain, skeletal muscle, and the reproductive
organs. LPA7/p2y5 is found in the skin and hair. Its ligand preference is LPA
18:2>18:1>20:4>18:0>16:0>14:0 (Yanagida et al., 2009). LPA8/p2y10 has been found in
the uterus, prostate, brain, lung, placenta, and skeletal muscle (Murakami et al., 2008).
The various species of LPA allows for the activation of specific LPA targets. In
addition to the different species, the LPA3 and P2RY5 receptors have shown a slight
preference for the sn-2 regioisomer over the sn-1 (Bandoh et al., 2000a; Yanagida et al.,
2009). However, the stability of the sn-2 regioisomer is still uncertain.
1.3.2 Intracellular Receptor, PPARγ
PPARγ is crucial for many biological responses. It is an active component of
regulating lipid and glucose homeostasis (Evans, 2005), cell proliferation (Mueller et al.,
1998), apoptosis (Elstner et al., 1998), and inflammation (Ricote and Glass, 2007; Tigyi,
2010). Due to these responses it plays a critical role in many diseases such as diabetes
(Lehmann et al., 1995), atherosclerosis (Li et al., 2000), and cancer (Sarraf et al., 1998).
PPARγ has been shown to only be activated by unsaturated LPA species and the Sstereoisomer.

7

1.4 ROLES OF LPA
1.4.1 LPA in Vascular Biology
LPA plays an important role in angiogenesis (Osborne and Stainier, 2003)
arteriosclerosis, inflammation, thrombosis, and is present in atherosclerotic lesions (Siess
and Tigyi, 2004). Atherosclerosis is the primary cause of heart disease and stroke
underlying about 50% of deaths in developed countries (Libby, 2002; Steinberg, 2002;
Zhang et al.; 2004). LPA has been identified as a biologically active lipid in mildlyoxidized LDL (mox-LDL), human atherosclerotic plaques, and supernatant of activated
platelets (Libby, 2002; Sano et al., 2002; Zhang et al., 2004). It is also known that serum
LPA level is significantly elevated in patients with acute myocardial infarction. More
importantly, mox-LDL and the lipid-rich core of human atherosclerotic plaques have
been shown to stimulate platelets through the activation of LPA receptors.
Atherosclerosis begins with neointima formation via the proliferation and migration of
vascular smooth muscle cells (VSMC) from the media to the intima. This results in
accumulation of lipids in the arterial intima, activation of macrophages, dedifferentiation
of vascular smooth muscle cells and endothelial injury (Libby, 2002). LPA has been
shown to elicit neointima formation when applied topically to the arterial wall (Zhang et
al., 2004).
1.4.2 The Role of LPA in Cancer
LPA provides cell survival advantages in an autocrine or paracrine fashion. ATX
has been found in many cancer cell types which provides a mechanism for generation of
LPA. One well established instance in which LPA has a role in cancer pathology is
ovarian cancer. Reports have shown that LPA levels in ovarian cancer ascites are highly
elevated (Xu et al., 1995; Baker et al., 2002; Sutphen et al., 2004) presumably due to an
increase in ATX expression (Xu et al., 1998; Dimova et al., 2006).
Expression of LPA2 mRNA was also shown to be upregulated in ovarian cancer
cells (Goetzl et al., 1999a) providing evidence of its involvement in ovarian cancer. LPA2
supports the aggressiveness of ovarian cancer in two different ways. First, it provides a
feed-forward loop by increasing the production of vascular endothelial growth factor
(VEGF), urokinase (uPA), and matrix metalloproteinases (MMP) (Zebrowski et al.,
1999; Hu et al., 2001; Huang et al., 2004; So et al., 2004; So et al., 2005) which in turn
upregulates ATX production and results in increased LPA levels (Ptaszynska et al.,
2008). Secondly, the LPA2 receptor mediates chemoresistance through its C-terminal
interaction of the thyroid receptor-interacting protein 6 (TRIP 6), Siva-1, and PDZ
binding proteins: NHERF2 and MAGI-3 (Yamada et al., 2005; Lin et al., 2007; Zhang et
al., 2007a; Zhang et al., 2007b; E et al., 2009). These findings provide a basis for the
importance of discovering receptor antagonists and ATX inhibitors for potential
anticancer therapeutics.
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1.4.3 LPA in Cell Survival and Apoptosis
Through its pro-mitotic and anti-apoptotic properties, LPA promotes cell survival.
LPA inhibits the activation of the mitochondrial apoptotic pathway which is further
linked to the activation of the ERK1/2 and Akt kinases (Goetzl et al., 1999b; Deng et al.,
2003; Radeff-Huang et al., 2004).
Because of its anti-apoptotic properties, LPA has been studied in a clinical role.
LPA can be used to reduce the side effects of radiation and chemotherapy in nonintestinal cancer patients because it reduces the damage to the intestinal epithelial cells
induced by gamma radiation and chemical agents that cause apoptosis (Deng et al.,
2002).
1.5 PHOSPHOLIPASES AND LYSOPHOSPHOLIPASES
1.5.1 Phospholipases
Phosphatidic acid contains two fatty acid chains and a phosphate esterified to a
glycerol backbone. The hydroxyl group at the C3 position of the glycerol is esterified to
phosphoric acid and is termed the sn-3 position. All major phosphoglycerides are derived
from phosphatidate. An ester bond is formed between the phosphate group of
phosphatidate and the hydroxyl group of an alcohol such as serine or choline.
Phospholipases cleave phospholipids to yield lysophospholipids. Phospholipase A1
(PLA1) cleaves at the sn-1 position whereas phospholipase A2 (PLA2) cleaves at the sn-2
position. A phospholipase B (PLB) enzyme will cleave at both the sn-1 and sn-2 position
and Phospholipase C (PLC) and phospholipase D (PLD) cleave on either side of the
phosphate group. The specificities of the phospholipases are shown in Figure 1.2.
Phospholipases are typically serine hydrolases, which are important in blood
coagulation, inflammation, and angiogenesis (Liu et al., 1999). Most serine hydrolases
are potently inhibited by fluorophosphonates (FP) or fluorophosphonate derivatives.
However fluorophosphonates do not inhibit cysteine, aspartyl, or metalloproteases (Liu et
al., 1999). FP’s reactivity requires that the serine hydrolase be in a catalytically active
state (Leung et al., 2003). This allows for much greater selectivity. Radiolabeled,
rhodamine-labeled, or biotin-labeled fluorophosphonate probes are available (Patricelli et
al., 1999). The rhodamine and biotin-labeled probes are rapid, selective and highly
sensitive. These probes have the fluorescent reactive group and the biotin tag coupled
through a long alkyl chain and two amide bonds (Liu et al., 1999).
FP- Rhodamine labeled probes can be used to label all active serine hydrolases
within a compound sample. Typical SDS gel electorphoresis can be used to separate
proteins and the fluorescent label can then be visualized using a flat-bed Infra-red
scanner. The biotinylated probes can be bound to avidin or streptavidin and separated
9

Figure 1.2 Specificity of phospholipases. Arrows indicate cleavage site of the indicated
phospholipase.
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from all other proteins. The biotinylated probe-bound serine hydrolase can then be
digested or boiled off the avidin beads and then this highly purified product can be
analyzed using LC-MS or gel electrophoresis.
1.5.2 Phospholipase A1
PLA1 catalyzes the cleavage of a glycerophospholipid at the sn-1 position
generating a sn-2 lysophospholipid and a fatty acid. Whereas many PLA2 isoforms have
been purified, cloned, and characterized, little is known of PLA1. A similar PLA1 to the
one we are studying has been described to some degree by Smith and Silver (Smith et al.,
1973). It has an acidic pH optimum of 4.8, but has not been biochemically identified and
cloned.
To date, there are two phosphatidic acid-selective cytosolic PLA1s named mPAPLA1α and mPA-PLA1β which are specifically expressed in human testis (Verheij et al.,
1981). It was shown that mPA-PLA1α and mPA-PLA1β hydrolyzed the ester bond at the
sn-1 position of phosphatidic acid to generate LPA, but did not hydrolyze the ester bond
of PC, PS, or PE (Verheij et al., 1981; Aoki, 2004).
Another known type of PLA1 is phosphatidylserine-specific PLA1 (PS-PLA1). PSPLA1 is secreted from rat platelets, but is not found in mouse or human platelets (Aoki et
al., 2002a; Smart et al., 2004). PS-PLA1 hydrolyzes PS, but does not hydrolyze PC, PE,
PI, or PA. PS-PLA1 is approximately 55kDa, stored intracellularly, and is secreted when
the cells are activated by thrombin, collagen, or calcium ionophore A23187 (Smart et al.,
2004). This suggests that under physiological conditions PS-PLA1 is secreted during rat
blood coagulation.
1.5.3 Phospholipase A2
Many forms of mammalian PLA2s have been identified. These include group IVA
Ca -dependent cytosolic PLA2 (cPLA2) (Leslie, 1997), group VI Ca2+-independent PLA2
(iPLA2) (Balsinde and Dennis, 1997), and secretory PLA2 (sPLA2) (Valentin and
Lambeau, 2000).
2+

Group IVA Ca2+-dependent cytosolic PLA2 (cPLA2) are 85kDa and are typically
located in the cytosol and translocated to the nuclear envelope and endoplasmic reticulum
upon activation (Schievella et al., 1995; Pouliot et al., 1996). cPLA2s have been shown to
play an important role in the arachidonic acid release, eicosanoid production and signal
transduction (Clark et al., 1995; Kramer and Sharp, 1997; Leslie, 1997).
Group VI Ca2+-independent PLA2 (iPLA2) are also 85kDa and have been shown
to play a key role in apoptosis and mediating basal phospholipid remodeling (Balsinde
and Dennis, 1996; Atsumi et al., 1998). It has been reported that this enzyme works as a
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multimeric complex of 270-350kDa through protein-protein interactions mediated by
ankyrin repeats (Ackermann et al., 1994; Larsson et al., 1998).
Secretory PLA2s have a molecular weight of 14-19kDa (Murakami and Kudo,
2004) and hydrolyze the ester bond at the sn-2 position of phosphoglycerides releasing
fatty acids and lysophospholipids. To date, ten secretory phospholipase A2s (sPLA2s)
have been identified in mammals (IB, IIA, IIC, IID, IIE, IIF, III, V, X, and XIIA)
(Schaloske and Dennis, 2006). Humans possess all except IIC (Murakami and Kudo,
2004). The mammalian family of sPLA2s are Ca2+ dependent. There are many known
inhibitors of sPLA2s including Me-Indoxam which is the most potent inhibitor for most
sPLA2s (Bacha et al., 2006).
1.5.4 Lysophospholipase D
Plasma lysoPLD cleaves lysophospholipids to produce LPA and was recently
identified as autotaxin (ATX) (Tokumura et al., 2002; Umezu-Goto et al., 2002), a
125kDa glycoprotein. ATX has been shown to promote tumor cell motility, metastasis,
and angiogenesis via a pertussis toxin-sensitive mechanism (Stracke et al., 1997; Nam et
al., 2001; Lee et al., 2002). LPLD/ATX is a member of the nucleotide
pyrophosphatase/phosphodiesterase (NPP) family and is also known as NPP2. NPP
family-members are capable of hydrolyzing adenosine triphosphate (ATP) and adenosine
diphosphate (ADP) in order to generate nucleoside 5’-monophosphates which
distinguishes them from other members of the lipase superfamily.
ATX contains a short N-terminal tail, a transmembrane domain, two cysteine-rich
somatomedin B-like domains, and a C-terminal catalytic domain. ATX mRNA is widely
expressed in the brain, ovary, lung, intestine, and kidney (Tice et al., 2002; Mills and
Moolenaar, 2003). ATX shows product feedback inhibition which is thought to
contribute to maintaining plasma levels of LPA in the nanomolar range (Durgam et al.,
2005; van Meeteren et al., 2005).
ATX has long been known as a tumor-motility factor which provides a link
between ATX and cancer. ATX has numerously been shown to be upregulated in several
human cancers and has been shown to enhance tumor aggressiveness (Nam et al., 2000)
perhaps through the generation of LPA.
1.5.5 Lysophospholipase A-I /II
As mentioned previously, lysophospholipases contribute to the breakdown of
LPLs by hydrolyzing the ester bond to produce a free fatty acid and a glycerolphosphate
derivative. There are large molecular mass Lysophospholipase As (LYPLAs) and small
molecular mass LYPLAs. Low molecular mass LYPLAs have been reported to be found
in rabbit heart (Gross and Sobel, 1983), pig gastric mucosa (Sunaga et al., 1995), murine
macrophage P388D1 (Zhang and Dennis, 1988; Zhang et al., 1991), rat and beef liver (de
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Jong et al., 1974; Sugimoto et al., 1996), and human HL60 cells (Garsetti et al., 1992).
Many of these tissues contain two isoforms: LYPLA-I and LYPLA-II which are similar
in size and have similar properties. For example, both enzymatic activities are
independent of Ca2+, Mg2+, and EDTA (Zhang et al., 1991; Garsetti et al., 1992; Sunaga
et al., 1995; Sugimoto et al., 1996). Despite their similarities, much evidence has been
reported to recommend that these enzymes are two distinct proteins. For example,
LYPLA-I has a much broader LPL substrate specificity than its LYPLA-II counterpart.
LYPLA-I has been shown to actively cleave LPC, LPE, LPG, LPI, LPS, and the acyl
analog of PAF, whereas LYPLA-II will only cleave LPE and LPC (Garsetti et al., 1992;
Sunaga et al., 1995; Sugimoto et al., 1996). LYPLA-I hydrolyzes both sn-1 and sn-2
regioisomers of LPC at identical rates (Wang et al., 1997).
Neither enzyme has been shown to have significant PLA1 or PLA2 activity in
rabbit heart, pig gastric mucosa, murine machrophage P388D1, or human HL60 cells
(Gross and Sobel, 1983; Zhang and Dennis, 1988; Zhang et al., 1991; Garsetti et al.
1992; Sunaga et al., 1995). However, these enzymes were only extensively characterized
using lysophospholipids substrates and human platelets have not been tested previously
for activity.
It is not uncommon for many phospholipases to show lysophospholipase activity
and all are typically grouped into the large molecular mass LYPLAs. Group IV Ca2+dependent cytosolic PLA2 exhibits strong lysophospholipase activity for sn-1 LPC but
shows little activity when presented with sn-2 LPC (Loo et al., 1997). Cytosolic Ca2+independent phospholipase A2 (iPLA2) also exhibits lysophospholipase activity along
with PLA1, transacylase, and PAF acetylhydrolase activity which has been shown to be
dependent on substrate presentation (Wolf and Gross, 1996; Lio and Dennis, 1998). PSPLA1 (Higashi et al., 1988; Yokoyama et al., 1995; Sato et al., 1997) and PA-PLA1
(Higgs and Glomset, 1996) also exhibit lysophospholipase activity as well as
phospholipase activity.
Another function of LYPLA-I/APT1 is the deacylation/depalmitoylation of G
proteins, ghrelin, and other thioacylated protein substrates (Duncan and Gilman, 1998;
2002; Hirano et al., 2009; Satou et al., 2010). The Km of the lysophospholipase activity is
about 8 times higher than the Km value of the thioesterase activity of the enzyme (Hirano
et al., 2009) indicating that LYPLA-I/APT1 has a much higher thioesterase activity than
lysophospholipase activity. However, the subcellular localization of the enzyme plays an
important role in the function of the enzyme.
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CHAPTER 2. THE PHOSPHOLIPASE A1 ACTIVITY OF
LYSOPHOSPHOLIPASE A-I LINKS PLATELET ACTIVATION TO LPA
PRODUCTION DURING BLOOD COAGULATION*
2.1 INTRODUCTION
Lysophosphatidic acid (LPA) is a multifunctional phospholipid mediator and
second messenger responsible for a wide variety of cellular responses (Pages et al., 2001;
Mills and Moolenaar, 2003; Tigyi and Parrill, 2003; Tigyi, 2010). LPA elicits its actions
through cell surface G protein-coupled receptors (Pages et al., 2001; Mills and
Moolenaar, 2003; Tigyi and Parrill, 2003; Tigyi, 2010) and through the nuclear
peroxisome proliferator activating receptor γ (PPARγ,Tsukahara et al.). LPA has been
shown to play a role in many physiological functions and human diseases (Pages et al.,
2001; Mills and Moolenaar, 2003; Tigyi and Parrill, 2003; Tigyi, 2010). The biochemical
pathways involved in LPA production in biological fluids are not yet fully understood.
LPA can be produced by several intra- and extracellular biochemical pathways.
Intracellularly, LPA is synthesized by a glycerophosphate acyl transferase-catalyzed
reaction of glycerol-3-phosphate with acyl-CoA in the endoplasmic reticulum and
mitochondria (Aoki, 2004; Gendaszewska-Darmach, 2008). LPA has also been shown to
be generated in a spatially regulated fashion by the Ca2+-independent phospholipase A2 at
the leading edge of migrating monocytes (Carnevale and Cathcart, 2001; Mishra et al.,
2008). Third, acylglycerol kinase phosphorylates monoacylglycerol to form LPA (Bektas
et al., 2005). A fourth pathway in humans, involves phosphatidylserine (PS)-specific
phospholipase A1 (PS-PLA1) that generates lysophosphatidylserine (LPS), which in turn
is converted to LPA by phospholipase D in mast cells (Nagai et al., 1999; Aoki et al.,
2002a).
Extracellularly, LPA can be produced by a secretory phospholipase A2 (PLA2)
(Fourcade et al., 1995), oxidative modification of low density lipoprotein (Siess et al.,
1999), or by the action of phosphatidic acid-specific phospholipase A1 (Aoki et al.,
2002a; Cummings et al., 2002). However, the most important pathway is a multi-step
process linked to the activation of platelets (Mauco et al., 1978; Schumacher et al., 1979;
Eichholtz et al., 1993; Gaits et al., 1997; Sano et al., 2002; Aoki et al., 2008). This
mechanism involves release of unidentified PLA1 and/or PLA2 enzymes from activated
platelets generating a new pool of lysophospholipid (LPL) substrates, which in turn are
* Adapted by permission: Alyssa L. Bolen, Anjaparavanda P. Naren, Sunitha Yarlagadda,
Sarka Beranova-Giorgianni, Li Chen, Derek Norman, Daniel L. Baker, Meng M.
Rowland, Michael D. Best, Takamitsu Sano, Tamotsu Tsukahara, Karoly Liliom,
Yasuyuki Igarashi, Gabor Tigyi. The Phospholipase A1 Activity of Lysophospholipase A-I
Links Platelet Activation to LPA Production During Blood Coagulation. Journal of Lipid
Research 2011, March 9. [Epub ahead of print].
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cleaved by the lysophospholipase D, autotaxin (ATX) (Tokumura et al., 2002; UmezuGoto et al., 2002). As a result of this mechanism, plasma LPA concentration rises from a
steady state concentration of approximately 100nM to serum concentrations up to 10µM,
with a significant increase in the content of polyunsaturated acyl species (Baker et al.,
2001; Sano et al., 2002; Hosogaya et al., 2008). The role of ATX in LPA production has
been clearly demonstrated by the decreased plasma LPA level in ATX knockout mice
(Tanaka et al., 2006; van Meeteren et al., 2006).
The rank order of the acyl species of LPA in normal human plasma is 18:2 > 18:1
> 18:0 > 16:0 > 20:4. In contrast, the rank order of the LPA acyl species in serum
changes to 20:4 > 18:2 > 16:0 > 18:1 > 18:0 (Sano et al., 2002). The various acyl species
of LPA also have differing ligand properties at target LPA GPCR (Fujiwara et al., 2005).
In addition to the differences in carbon chain length and degree of unsaturation, the LPA3
and P2RY5(LPA6) receptors also show a preference for the sn-2 over the sn-1 acyl
regioisomer of LPA (Bandoh et al., 2000b, Yanagida et al., 2009). However, the sn-2
LPA regioisomer is relatively unstable. At neutral pH acyl migration begins immediately
to yield the more thermodynamically stable sn-1 regioisomer, an equilibrium ratio of 9:1
occurs between the two forms (Pluckthun and Dennis, 1982).
The linoleoyl- (18:2) and arachidonoyl (20:4) species make up 84% of the LPA
found in serum (Sano et al., 2002). The mechanism behind the enrichment and increase
in polyunsaturated LPA species upon blood coagulation is still unknown. Because plasma
phospholipids containing 18:2 and 20:4 fatty acids are almost exclusively esterified to the
sn-2 glycerol carbon, we hypothesized that LPA in serum enriched in these fatty acyl
species must be generated by the action of a PLA1 enzyme (Sano et al., 2002). This
hypothesis implies that the nascent sn-2 LPL generated by PLA1 will either be rapidly
cleaved by ATX and then undergo acyl migration or alternatively, undergo acyl
migration prior to headgroup cleavage. Distinguishing between the latter two possibilities
is challenging due to the short half-life of the sn-2 LPLs that precludes the use of
classical biochemical separation and analytical techniques.
In the present study, we sought to identify the putative PLA1 enzymes released
from activated platelets that are responsible for the generation of polyunsaturated LPL.
Starting with the supernatants from thrombin-activated human platelets, we isolated
lysophospholipase A1/acyl protein thioesterase (LYPLA-I/APT1) using a series of
chromatographic steps and fluorophosphonate-biotin affinity labeling-based proteomics.
LYPLA-I/APT1 transcripts were subsequently shown to be abundantly expressed in
platelets and in megakaryocytes. LYPLA-I/APT1 was found to posses PLA1 activity
against plasma phospholipids, did not degrade LPA, and increased LPA production when
added to plasma through the production of a pool of LPL, which is further cleaved by
ATX.
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2.2 MATERIALS AND METHODS
2.2.1 Materials
Fluorescently labeled 1-oleoyl-2-{12-[(7-nitro-2-1,3-benzoxadiazol-4yl)amino]lauroyl}-sn-glycero-3-phosphoserine (NBD-PS 18:1-12:0), 1-oleoyl-2-[12-[(7nitro-2-1,3-benzoxadiazol-4-yl)amino]lauroyl]-sn-glycero-3-phosphocholine (NBD-PC
18:1-12:0), dioleoyl phosphatidylserine (PS), linolenoyl phosphatidylcholine (PC),
oleoyl lysophosphatidic acid (LPA), LPC 17:0, and LPA 17:0 were purchased from
Avanti Polar Lipids, Inc. (Alabaster, AL). 1-Oleyl-sn-glycero-3-phosphocholine (LPAF
18:1) was purchased from Bachem (Torrance, CA). Fluorophosphonate-Rhodamine (FPRH) and fluorophosphonate-biotin (FP-Biotin) were a gift from Dr. Ben Cravatt (Scripps
Institute, La Jolla CA). Freshly expired apheresis platelets were provided by The
Regional Medical Center (Memphis, TN), Methodist University Hospital (Memphis,
TN), or purchased from Key Biologics, Inc. (Memphis, TN). PGE1 and thrombin were
obtained from Sigma-Aldrich (St. Louis, MO). Trizol and Superscript III OneStep RTPCR was purchased from Invitrogen (Carlsbad, CA).
2.2.2 Isolation and Activation of Human Platelets
The procedures detailed below were reviewed and approved by the Institutional
Review Board of the University of Tennessee Health Science Center. Small-scale
batches of platelet rich plasma (PRP) were prepared by adding 3.6mL acidic citrate
dextrose (ACD, 0.8% citric acid, 2.2% sodium-citrate, 2.45% glucose) to 20mL of cubital
venous blood drawn from a volunteer donor and centrifuged at 180 x g for 15min. The
top layer of platelet rich plasma (~10mL) was transferred to a new tube. For large scale
purifications, units of freshly expired apheresis platelets in ACD were obtained
(approximately 60mL per unit). Then 10mL of the PRP from the small scale purification
or 10mL of the aphersis platelets were diluted with 34mL Buffer A (138mM NaCl,
3.3mM NaH2PO4, 2.9mM KCl, 1mM MgCl2, 20mM HEPES, 1mg/mL glucose, pH 7.5),
and 1µM PGE1 was added. The diluted PRP was centrifuged at 1400 x g at room
temperature for 15min. The supernatant was discarded and the pellet containing the
platelets was reconstituted in 2mL buffer A and 2mM Ca2+ was added. The platelets
were activated using 1U thrombin per 1mL sample at 37°C for 20min and the aggregate
formed was centrifuged at 9,300 x g for 5min to yield supernatant 1 (Sup1). The Sup1
was then centrifuged again at 100,000 x g for 45min to remove platelet microvesicles.
This preparation was designated as supernatant 2 (Sup2).
2.2.3 Measurement of Phospholipase A1 Activity
PLA1 activity was measured by determining the amount of
lysophosphatidylcholine (LPC) or lysophosphatidylserine (LPS) generated after
incubation of sample with phosphatidyl choline (PC) or phosphatidyl serine (PS). NBD16

PC or NBD-PS (45ng to 2µg) was incubated in 10mM Tris (pH 7.5) or Sup2 (pH 7.5) at
37°C for 1min to 1 hour with or without the presence of an equal weight of BSA in water.
For quantification, 900 ng, 90 ng, and 9 ng of the fluorescent substrates were incubated
without enzyme for construction of a standard curve by plotting fluorescence intensity as
a function of substrate mass. Water-saturated butanol (BuOH) was added (30-120µl) to
stop the reaction and extract the lipids. Samples (10µl) were spotted on Silica Gel 60 thin
layer chromatography (TLC) plates. The plates were then developed with solvent A
consisting of chloroform:methanol:ammonium hydroxide (V/V/V, 6:4:1) for NBD-PS
and solvent B consisting of chloroform:methanol:28% ammonium hydroxide:water
(V/V/V/V, 50:40:8:2) for NBD-PC. The products were visualized using a Fotodyne
imager (Hartland, WI) and quantified by the TotalLab100 software. The amount of the
product generated was determined by interpolation from the standard curve. The Rf
values for the various lipids were as follows: NBD-PC: 0.54, NBD-LPC: 0.38, NBD-FA:
0.77, NBD-PS: 0.45, NBD-LPS: 0.33, NBD-FA: 0.67.
For unlabeled substrates, 10µg PC, PS, or LPA was digested at 37°C for 1 hour in
the presence of 10µg BSA. LPC 17:0 and LPA 17:0 (500-2000 ng in DMSO) internal
standards were added prior to addition of 60µl BuOH. The samples were vortexed for
1min and the BuOH phase was isolated by centrifugation at 14000 x g for 1 min and
dried under argon. The lipid extract was reconstituted in 30µl
methanol:acetonitrile:Isopropanol:water (V/V/V/V, 1:1:1:1). LPC and LPA
concentrations were determined by liquid chromatography-mass spectrometry (LCMS/MS) using an Applied Biosystems Sciex ABI 4000 QTRAP tandem mass
spectrometer (Foster City, CA) equipped with a TurboionsprayTM interface, a Shimadazu
LC-10ADvp HLPC pump (Columbia, MD) with a Leap HTS PAL autosampler
(Carrboro, NC). Samples (10µl) were injected onto a Tosoh TSK-ODS-100Z silica
column (150 mm x 2mm; 5-μm particle size) with a solvent consisting of methanol/water
(V/V, 95:5), 5mM ammonium formate using an isocratic flow rate of 0.22mL/min
(Tokumura et al., 2009). The spectra were processed using Analyst software, version 1.5.
The molecular species of LPC and LPA were analyzed by multiple reaction monitoring
(MRM) in positive ion mode for LPC and negative ion mode for LPA. The Q3 (product
ion) was set at m/z 184.0 for LPC and 153.0 for LPA (glycerophosphate moiety)
(Tokumura et al., 2009). Q1 was set for the neutral molecular ion for all LPLs.
Quantification was done by calculating the ratio of peak area to that of the appropriate
LPC/LPA 17:0 internal standard.
2.2.4 Partial Purification of PLA1
PLA1 was partially purified using sequential chromatography on an AKTA FPLC
system (GE Biosciences, Piscataway, NJ) by loading 330mg (75mg/ml) Sup2 to a Q
Sepharose Fast Flow ion exchange chromatography column (GE Biosciences, 2 cm x 10
cm). The column was eluted with a NaCl gradient (0-1M) at a 1mL/min flow rate over
20min with buffer C (3.3mM NaH2PO4, 2.9mM KCl, 1mM MgCl26H2O, 20mM
HEPES, pH 7.5). The PLA1 active fractions were combined and 5mL (~30mg) was
loaded onto a Butyl-Sepharose hydrophobic interaction chromatography column (GE
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Biosciences, 0.7cm x 2.5cm, 20mg/mL medium). The column was eluted using a gradient
from 1.7M to 0M (NH4)SO4 over 20min in 0.05M Na2HPO4 buffer (pH 7.6). The active
fractions were combined and 5mL (~2.5mg) was loaded onto a HiTrap Blue affinity
chromatography column (GE Biosciences, 0.7cm x 2.5cm). The column was eluted by
increasing (NH4)SO4 from 0 to 1.7M over 20min in 0.05M Na2HPO4 buffer (pH 7.6).
3mL Fractions were collected at each step. 100µl of each fraction was used for PLA1
activity measurement using 1µg NBD-PS substrate at 37°C for 2 hours. 120µl watersaturated BuOH was added to stop the reaction and extract the lipids. The samples were
vortexed and centrifuged for 1min at 14,000 x g. 10µl of the BuOH phase was spotted to
a Silica Gel 60 TLC plate. The plate was developed with solvent A and the products were
visualized. The fractions with PLA1 activity from each chromatographic step were
combined, activity was determined as described, and protein concentration was
determined by BCA protein assay (Pierce, Rockford, IL) following the manufacturer’s
protocol.
2.2.5 FP-Rhodamine Labeling
An amount of 50µg protein of the PLA1 active Butyl-Sepharose pooled fractions
(~100µl) and 0.9µg NBD-PS substrate was incubated at 37°C for 3 hours with 0.03, 0.1,
0.3, 1, 3, 10, and 30µM FP-Rh. Then 60µl water-saturated BuOH was used to stop the
reaction and extract the lipid products. After mixing, the samples were centrifuged for
1min at 14000 x g. Then 10µl of the BuOH phase was spotted to a Silica Gel 60 TLC
plate and developed with solvent A. The products were visualized using a Photodyne
imager and quantified using standards run alongside the samples on the same TLC plate.
2.2.6 FP-Biotin Labeling and Purification
The activity-based proteomic probe, FP-Biotin, was used to label all serine
hydrolases in the PLA1-active HiTrap Blue fractions. An active pool of HiTrap Blue
chromatography fractions was concentrated using an Amicon concentrator (Millipore,
Billerica, MA) with a 5kDa molecular weight cutoff. An amount of 1mg protein
(1mg/mL) was incubated for 2 hours with a final concentration of 5µM FP-Biotin.
Streptavidin beads (Pierce, Rockford, IL) were then pre-washed three-times with binding
buffer (0.1M sodium phosphate, 0.15M NaCl, pH 7.0) followed by centrifugation (3000 x
g for 1min) and the supernatant was discarded. The protein complex was added to 50µl
resin and incubated with mixing for 1hr at room temperature. Streptavidin-bound FPBiotinylated proteins were washed with binding buffer in the presence of 4M urea, 0.1%
SDS (W/V), and 0.2% TritonX-100 (V/V) (pH 7.2) and centrifuged for 1min at 3000 x g.
The supernatant was removed and the wash procedure was repeated four times. The
beads were reconstituted in 1mL 50mM TRIS-HCl (pH 7.2) centrifuged for 4min at
10000 x g and the supernatant was decanted. 200µl 50mM TRIS-HCl (pH 7.2) was
added to reconstitute the final pellet.
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2.2.7 Proteomic Analysis of FP-Biotin-Labeled Products in Partially Purified
Platelet Supernatants
The bead-bound FP-Biotin-labeled proteins were first reduced with 5mM
dithiothreitol for 30min at room temperature and alkylated with 10mM iodoacetamide at
room temperature in the dark for 30min. The sample was centrifuged for 4min at 10000
x rpm and 100µl of supernatant was removed. A total of 300µl 50mM TRIS (pH 7.2)
buffer and 1.5µl of 0.5µg/µl trypsin (sequencing grade, Sigma-Aldrich, St. Louis, MO)
was added and incubated at 37°C for 12 hours. The sample was centrifuged for 4min at
10000 x rpm and the supernatant containing the peptide digest was transferred to a new
tube; formic acid was added to a final concentration of 5% (V/V). The volume of the
peptide sample was reduced to 40µl in a vacuum centrifuge. The peptides were desalted
with a Zip Tip C18 microcolumn (Millipore, Billerica, MA) using the procedure
recommended by the manufacturer. Peptides were eluted using 4µl of 50%
acetonitrile/0.1% trifluoroacetic acid (V/V). Four microliters of water/acetic acid (0.5%)
were added to the sample. LC-MS/MS experiments were performed on an LTQ linear
ion trap mass spectrometer (Thermo Scientific, Waltham, MA) coupled to a nanoflow LC
system (Dionex, Sunnyvale, CA). The peptide sample was injected onto a fused-silica
capillary column/spray needle (15 cm length, 75µm ID; New Objective, Woburn, MA)
packed in-house with C18 stationary phase (Michrom Bioresources, Auburn, CA). The
peptides were separated with a 90 min-gradient from 0% to 90% of mobile phase B. The
composition of mobile phase B was 90% MeOH/10%water/0.05% HCOOH; the
composition of mobile phase A was 2% MeOH/98% water/0.05%HCOOH. Mass
spectrometric data acquisition was performed in the data-dependent mode; one cycle
encompassed a full-range MS scan followed by 7 MS/MS scans on the most abundant
ions from the MS scan. The LC-MS/MS data were used to search the SwissProt protein
sequence database (subset of human proteins), using the program Bioworks/Sequest
(Thermo Scientific).
2.2.8 RNA Purification and RT-PCR
A total of 100ml of venous blood was drawn into 20mL ACD, 1 µM PGE1. The
blood was centrifuged at 180 x g and the platelet rich plasma was filtered through a PL6T
leukocyte reduction filter (Pall, Inc., Port Washington, NY). Buffer A (68mL) and 12mL
ACD was added to the sample and centrifuged at 1400 x g. The supernatant was
removed, the platelet pellet was resuspended in 1mL Trizol (Invitrogen) and RNA was
extracted following the manufacturer’s protocol. Two gene- and species-specific primers
for each candidate protein were designed. Each primer was designed to produce a product
between 250 and 350 basepairs-long and span an intron of more than 1000 base pairs so
that DNA contamination would easily be identifiable by the size of the product. The
following primers were used: LYPLA-I/APT1 1: 5’-GCAGAAGCCTT TGCAGGTAT 3’, forward 5’-ATTGCCATTCTTCACTTCTTGAT-3’, reverse; LYPLA-I/APT1 2: 5’ACTCAGTTGCTGGCTTCCAC-3’, forward 5’-TGCTTGACATCCATCATTTCC-3’,
reverse; MGLL 1: 5’-GCTGGACCTGCTGGTGTT-3’, forward 5’19

TGTTGCAGATTCAGGATTGG-3’, reverse; MGLL 2: 5’AAGGGGCCTACCTGCTCAT-3’, forward 5’-TGGCTGTCCTTTGAGAGACC-3’,
reverse; PLA1A 1: 5’-CCAATGATGTGGATTGAGGA-3’, forward 5’GAAGCCATCCACACAGACAC-3’, reverse; PLA1A 2: 5’GCTGTGGGCAGCTAGTAGAAC-3’, forward 5’-CCAATGATGTGGA TTGAGGA3’, reverse; LCAT 1: 5’--3’, forward 5’--3’, reverse; LCAT 2: 5’-GCTCCTCAAT
GTGCTCTTCC-3’, forward 5’-CGGTAGCACATCCAGTTCAC-3’, reverse. Reversetranscription polymerase chain reaction was done using the Superscript III kit
(Invitrogen). 30 cycles were performed using 400ng RNA template. The PCR products
were separated on 2% agarose gels and visualized with ethidium bromide staining.
2.2.9 MGLL Activity Assay
Human recombinant MGLL was purchased from Abnova Corporation (Jhongli,
Taiwan) and 0.5µg enzyme was incubated with NBD-PS (0.9µg) for 3 hours at 37°C in
20µl 10mM TRIS (pH 7.5). Then 30µl water-saturated BuOH was added to extract the
lipids and 10µl of the extract was spotted on a TLC plate. The plates were then developed
with solvent A consisting of chloroform:methanol:ammonium hydroxide (V/V/V, 6:4:1).
The products were visualized using a Fotodyne imager (Hartland, WI) and quantified by
the TotalLab100 software. The amount of the product generated was determined by
interpolation from the standard curve.
Recombinant monoglyceride lipase (MGLL) was purchased from Abnova
Corporation (Jhongli, Taiwan) and tested for activity using an assay kit from Cayman
Chemicals (Ann Arbor, Michigan) that utilizes the hydrolysis of the thioester bond of
arachidonoyl-1-thio-glycerol to produce a free thiol that reacts with 5,5'-dithiobis-(2nitrobenzoic acid) (DTNB). Recombinant MGLL (0.3µg or 0.5µg) or 100µl PLA1-active
Blue-Sepharose fraction was added in 150µl total volume with assay buffer (10mM
TRIS-HCl, 1mM EDTA, pH 7.2), to a 2.7mM ethanolic solution of arachidonoyl-1-thioglycerol and incubated at room temperature for 5 min. The absorbance was read at
415nm using a BioTek microplate reader.
2.2.10 Construction of Recombinant LYPLA-I/APT1 Expression Plasmid
Human full length LYPLA-I/APT1 (Accession # AF081281) was PCR-amplified.
The PCR products were cleaned using the Qiagen PCR purification kit and eluted in 20µl
DNA grade water. The DNA was used for ligation independent cloning (LIC) using the
Ek/LIC cloning kit from Novagen (EMD, Gibbstown, NJ). Primers used for LIC cloning
were: LYPLA-I/APT1-full-length-LIC Forward: GACGACGACAAGATGTGCGGCAA
TAACATGTCAACC and LYPLA-I/APT1-full-length-LIC Reverse: GAGGAGAAG
CCCGGTTCAATCAATTGGAGGTAGGAG. PCR-purified DNA (14.6µl) was taken
into a sterile centrifuge tube and 2µl each of 10-times concentrated T4 DNA polymerase
buffer and 25mM dATP were added. Dithiothreitol 1µl, 100mM and 0.4µl of T4 DNA
polymerase were added to start the reaction with gentle stirring at 22°C for 30min. The
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reaction was stopped by incubation at 75°C for 20min. This T4 DNA polymerase-treated
insert can be annealed into any Ek/LIC vectors including the pET-41 vector used here.
For the ligation reaction, 1µl Ek/LIC vector (pET-41) and 2µl of T4 DNA polymerasetreated insert were used and incubated at 22°C for 5min. Then, 1µl of 25mM EDTA was
added for 5min at 22°C. The ligated product was transformed into Novablue cells (EMD
biosciences, Gibbstown, NJ). Three transformants were picked, and plasmid DNA was
isolated and sequenced. The sequences were confirmed to be that of LYPLA-I/APT1.
2.2.11 Recombinant LYPLA-I/APT1 Purification
GST-LYPLA-I/APT1 was purified from transformed BL21-DE3 E. coli bacteria.
Protein expression was induced using 200μM isopropyl β-D thiogalactopyranoside.
Bacteria were pelleted by centrifugation and resuspended in lysis buffer (50mM TRIS
base, 1mM EDTA, and 10% sucrose containing the protease inhibitors; aprotinin
1μg/mL, leupeptin 1μg/mL, pepstatin 1μg/mL, and PMSF 500μM). Lysozyme (1mg/mL)
was added to the resuspended bacteria and allowed to mix at 4°C for 30min. NP40 was
added to the suspension (0.2% final concentration) and allowed to mix at 4°C for 30min.
The suspension was cleared by centrifugation at 14000 x g for 30min at 4°C. Glutathione
beads (ThermoFisher Scientific; 2mL of 50% slurry) were added to the cleared
supernatant and allowed to mix for 2 hours at 4°C. Glutathione beads were retrieved by
centrifugation and washed with 0.2% Triton-X-100 (V/V) in phosphate buffered saline
(PBS) three-times, followed by a wash with PBS plus protease inhibitors. A 20μL sample
of the protein bound to the glutathione beads was eluted using Laemmli sample buffer
and run on a 4-15% gel to visualize the quantity and purity of the isolated protein. Protein
was eluted from the beads using 20mM reduced glutathione (pH 7.8) and dialyzed against
an appropriate buffer and protein and stored in small aliquots at -80oC.
The GST- tag was removed by thrombin cleavage using 1 mg of GST-LYPLAI/APT1 mixed with 2.5 units of biotinylated thrombin (Novagen, Darmstadt, Germany) in
20mM TRIS-HCl (pH 8.4), 150mM NaCl, 2.5mM CaCl₂ buffer at 20⁰C for 16h. After
cleavage, the biotinylated thrombin was removed using streptavidin-agarose (Novagen,
Darmstadt, Germany) using a ratio of 16:1 settled resin per unit of enzyme.
Recombinant protein was tested for PLA1 activity by incubating 0.5µg of
LYPLA-I/APT1 or 0.05µg GST-LYPLA-I/APT1 with 0.9µg BSA and 0.9µg NBD-PS in
20µl of 10mM TRIS-HCl (pH 7.6) for 15min at 37°C. Water-saturated BuOH (30µl) was
added to stop the reaction and extract the lipids after centrifugation. Samples (10µl) of
the BuOH phase were spotted on Silica Gel 60 TLC plates which were developed with
solvent A. The products were visualized using a Fotodyne imager.
2.2.12 Monitoring LPC and LPA Production in Plasma
Blood (5ml) was drawn into a heparinized or non-treated Vacutainer tubes. Blood
was centrifuged at 14000 x g for 1min and the PRP was transferred to a new tube. The
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PRP from the tube with no additive was allowed to clot to generate serum. An amount of
10µg recombinant LYPLA-I/APT1 enzyme was added to 1mL activated plasma and
incubated at 37°C for 24 hours alongside 1mL activated plasma without addition of the
enzyme. The internal standards 17:0 LPA and 17:0 LPC (20ng each) were added to 200µl
of the fresh PRP or to 200µl of the serum samples after 24 h incubation. A total of 200µl
of citrate phosphate buffer (30mM citric acid and 40mM Na2HPO4, pH 4.0), 400µl
methanol, and 200µl chloroform were added to the samples and centrifuged at 14000 x g
for 1min. The chloroform layer was transferred to a new tube, dried under argon gas and
reconstituted in 30µl methanol:acetonitrile:isopropanol:water (1:1:1:1). LPA 18:2 and
LPA 20:4 were quantified by LC-MS/MS/MS as described above.
2.2.13 Synthesis of sn-2 lyso-PAF 18:1
Synthesis and characterization of sn-2 lyso-PAF 18:1 is described in the
accompanying Supplemental information.
2.2.14 Determinination of Regioisomeric Selectivity of ATX Against Two Lyso-PAF
Substrates
Serial dilutions of either sn-1 or sn-2 LysoPAF 18:1 (2 mM – 31.25 µM, in 20µl
assay buffer, 50mM TRIS, pH7.4, 5mM CaCl2, 1mg/mL BSA) were added to the wells in
a 96 well, half area plate. A total of 20µl of either 10nM ATX (final concentration) or
assay buffer were also added to the wells along with 20µl Amplex Red cocktail (10µM
Amplex Red, 0.1 Unit/mL choline oxidase (CO), and 1 unit/mL horse radish peroxidase
(HRP), final concentration (Amplex Red, Invitrogen, Carlsbad CA; CO, MP Biomedical,
Solon OH; HRP, ThermoFisher Scientific, Waltham, MA). The plate was incubated at
37°C for 6 hours and was read at excitation/emission wavelengths of 530/590nm every 2
minutes with a BioTek Synergy 2 plate reader (Winooski, VT). A linear segment of time
vs concentration of product was plotted for each substrate concentration to determine
initial reaction velocity. In order to calculate product concentration, a linear segment of
absorbance values of serial dilutions of resorufin (2000 - 0.0004768µM) was used to
establish a calibration curve of resorufin fluorescence. Resorufin and product
concentration are directly proportional in the Amplex Red assay, thus experimental
absorbance values were then interpolated on the calibration curve to determine product
concentration. Substrate concentration vs initial velocity was then plotted using GraphPad
Prism® version 5.0a for Mac OS X, and a rectangular hyperbolic curve fit was used to
define kinetic parameters.
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2.3 RESULTS
2.3.1 Phospholipases Released from Activated Platelets Generate Lysophospholipids
but LPA Production Requires ATX from Plasma
Platelet activation triggers an upsurge in production of LPA molecular species
predominantly with 18:2 and 20:4 fatty acids (Mauco et al., 1978; Schumacher et al.,
1979; Eichholtz et al., 1993; Gaits et al., 1997; Baker et al., 2001; Sano et al., 2002; Aoki
et al., 2008). Using biosynthetic labeling of platelet phospholipids it has been shown that
only trace amounts of 32P-LPA were found in the supernatant of activated platelets (Sano
et al., 2002). To extend this observation concerning the lack of LPA production by
platelets we tested the hypothesis that platelets secrete phospholipase(s) that de novo
generate a pool of LPL that in turn serve as substrates for ATX constitutively present in
plasma (Tokumura et al., 1986; Tokumura et al., 1998; Tokumura et al., 2000). The first
question we raised in pursuing this hypothesis was whether platelet activation by
thrombin leads to the release of PLA1 detectable in the supernatant. To determine this
PC18:2 (Figure 2.1A), PS18:1 (Figure 2.1B), NBD-PC (Figure 2.1C), or NBD-PS
(Figure 2.1D) were incubated with Sup2 in the presence or absence of ATX. We found
significant LPC generation in Sup2 regardless of whether we used PC 18:2 or NBD-PC
as substrate. However, very little LPA was produced. Using the fluorescent NBD-PC
substrate LPA production was below the level of detection of our assay; however, using
mass spectrometry we detected a 0.028 ± 0.06ng/µg/h rate of LPA production. When PS
18:1 was used for substrate we observed the production of LPS 18:1 and a higher rate of
LPA production amounting to 4.2 ± 0.8ng/µg/h. However, using NBD-PS we still were
unable to detect LPA production. In contrast, when recombinant human ATX was added,
a 9.5 fold increase in the amount of LPA generated from LPC and a 2 fold increase in the
amount of LPA generated from LPS with a concomitant decrease in the LPC or LPS was
observed. When NBD-PC or NBD-PS analogs were used, essentially the same findings
were noted validating the applicability of these fluorescent analogs for monitoring LPL
production. The finding of high rates of LPC and LPS production in the Sup2 suggest
that phospholipases are secreted from platelets, but lysophospholipase D is not present in
sufficient quantity to provide for substantial LPA production. The results with NBD
phospholipids indicate that substantial amounts of PLA1 activity are present in Sup2
because the predominant product formed was NBD-LPC and NBD-LPS with the
fluorescent label in the sn-2 position. We hypothesized that phospholipase(s) A1 are
secreted upon activation of platelets and we next attempted to purify these enzymes.
2.3.2 Partial Purification of Phospholipase A1 from Supernatants of Activated
Human Platelets
To further substantiate the hypothesis that a novel PLA1 is secreted from platelets
we partially purified this enzyme from Sup2. Sup2 from human platelets was prepared
and applied to Q Sepharose Fast Flow ion exchange chromatography using an AKTA
FPLC system. Fractions (3mL) were collected and each fraction was assayed for PLA1.
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Figure 2.1 ATX is required for LPA production in activated platelet supernatant.
Supernatant from thrombin-activated human platelets was incubated in the absence or
presence of recombinant human ATX with 10µg PC 18:2 (panel A), 10µg PS 18:1 (panel
B), 1µg NBD-PC 18:1/12:0 (panel C), or 1µg NBD-PS 18:1/12:0 (panel D) supplemented
with 250µM BSA and 135mM NaCl in the presence or absence of 200nM ATX at 37°C
for 1 hour. Generation of the corresponding LPC and LPA species was quantified using
LC/MS (panels A & B) or TLC (panels C & D). In the absence of added ATX very little
LPA was produced. In sharp contrast, LPC was abundantly generated by a PLA activity.
Addition of ATX leads to a 9.5-fold increase in the amount of LPA generated from LPC
and a 2-fold increase in the amount of LPA generated from LPS with a concomitant
decrease in the LPC or LPS. When the unnatural NBD-PC/PS analogs were used,
essentially the same findings were noted validating the usability of these fluorescent
analogs for monitoring LPA production. Bars are the mean of 3 independent
determinations ± S.D.
.
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activity using NBD-PS as a substrate. Most PLA1 activity with low PLA2 activity
contamination was found in the last portion of the flow-through fractions and no PLA1
activity was detected in the bound fractions. The active fractions were combined and
concentrated using a 5kDa Amicon concentrator to exchange the buffer and load onto a
Butyl-Sepharose column. The resulting active fractions were then loaded onto a HiTrap
Blue affinity chromatography column to eliminate albumin from the sample and the
PLA1 was recovered from the flow through and concentrated as above. The specific PLA1
activity present in the various pooled fractions is shown in Table 2.1. The three
chromatographic steps resulted in a 1500-fold purification of PLA1 activity
2.3.3 Activity Based Purification of Platelet PLA1
Even though the multistep chromatographic purification yielded a 1500-fold
enrichment of PLA1 activity the sample contained multiple protein bands when examined
using SDS-PAGE. Further chromatographic purification led to loss of activity
necessitating a change in the purification strategy. Most phospholipases contain a serine
in the catalytic site which selectively reacts with fluorophosphonate (FP) (Leung et al.,
2003). Most serine hydrolases are potently inhibited by FP or its derivatives. However,
FPs do not inhibit cysteine, aspartyl, or metalloproteases (Liu et al., 1999). Rhodamineand biotin-labeled FP probes are rapid, selective, and are highly sensitive affinity labels
for serine hydrolases. In these probes the fluorescent reactive group or the biotin tag is
coupled through a long alkyl chain and two amide bonds (Liu et al., 1999).
We first determined if the PLA1 activity present in platelets reacted with a FP
probe. A Butyl Sepharose fraction was incubated with incremental amounts of FP-RH
and NBD-PS substrate. An increase in concentrations of FP-RH produced a decrease in
NBD-LPS production presumably due to a competition between FP-RH and NBD-PS for
the catalytic site of PLA1 (Figure 2.2A). This experiment provided evidence that PLA1
was a serine hydrolase and reacted with FP probes. FP-RH optimally inactivated PLA1 at
5µM and 2h of incubation (data not shown).
2.3.4 Identification of Serine Hydrolases Secreted from Thrombin Activated Human
Platelets
Since we determined that PLA1 reacted with the FP probes, we then labeled the
partially purified PLA1 obtained after the HiTrap Blue chromatography step with FPbiotin. The FP probe allowed us to selectively label all serine hydrolases present in our
sample and the biotin allowed us to isolate the labeled proteins using streptavidin beads.
We analyzed samples from three different purifications. Tandem mass spectrometry
(MS/MS) data were obtained for the tryptic peptides present in the digest. The MS/MS
data, which are diagnostic of the peptide sequences, were used to identify the proteins of
interest through protein database searches. Based on LC-MS/MS data, four relevant
candidate proteins were identified: lecithin-cholesterol acyltransferase (LCAT),
phosphatidylserine specific phospholipase A1 (PS-PLA1), monoglyceride lipase (MGLL),
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Table 2.1 Summary of chromatographic steps.
Step

µg protein/µl
75.3 +/- 6.2

Specific activity
(units*/µg)
0.10 +/- 0.03

Purification
(fold)
1

Platelet
supernatant
(Sup2)
Q sepharose

16.2 +/- 1.7

1.6 +/- 0.4

16

Butyl
sepharose

0.08 +/- 0.02

89.2 +/- 4.4

872

HiTrap blue
0.03 +/- 0.01
159.5 +/ 27.6
*Units defined in nanomoles of LPS formed/h at 37°C.
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Figure 2.2 FP-Rhodamine binds to PLA1 inhibiting activity and NBD-LPS
production. Incremental amounts of FP-Rhodamine were incubated with NBD-PS and a
phospholipase A1 active Butyl Sepharose fraction (panel A). The production of NBDLPS decrease with increasing amounts of FP-RH. Expression of serine hydrolase
transcripts in human platelets (panel B). RT-PCR for LYPLA-I/APT1, MGLL, PS-PLA1
and LCAT was performed using two different gene-specific primer pairs (denoted 1 & 2)
using mRNA isolated from human purified platelets. Only LYPLA-I/APT1 and MGLL
amplification yielded PCR products of the expected size indicating the expression of
these enzymes in human platelets. These results have been confirmed with platelets from
5 other donors of both sexes. MGLL does not possess PLA activity (panels C & D).
When incubated with NBD-PS no LPS was formed thereby indicating MGLL does not
possess PLA activity (panel C). Human recombinant MGLL was shown to have MGL
activity to prove functionality (panel D). Bars are the mean of 3 independent
determinations ± S.D.
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and lysophospholipase A-I also known as acyl protein thioesterase 1 (LYPLA-I/APT1)
(Table 2.2).
Because we used platelet rich plasma as a starting material, plasma protein
contamination in our sample was a possibility, hence it was important to determine
whether the proteins identified in the sample were expressed in platelets. To this end,
mRNA was isolated from human platelets and RT-PCR for LYPLA-I/APT1, MGLL,
PLA1A and LCAT was performed using two different gene-specific primer pairs
(denoted 1 & 2, Figure 2.2B). The eight primer sets were validated to amplify the
appropriate transcripts derived from selected tissues. Only two of the four lipases
identified by LC-MS/MS, namely LYPLA-I/APT1 and MGLL, yielded PCR products of
the expected size indicating the expression of these enzymes in human platelets.
We hypothesized that either MGLL, LYPLA-I/APT1, or both might play a role in
LPA production during blood coagulation. In order to determine whether any of these
proteins is involved in LPA production we needed to first establish if either enzyme
possessed PLA1 enzymatic activity. Human recombinant MGLL was tested for PLA1
activity (Figure 2.2C). No cleavage of NBD-PS or generation of NBD-LPDS product was
detected suggesting that it does not function as a PLA1. Using as much as 0.5µg
recombinant MGLL in a MGL activity assay (Figure 2.2D) we verified that the enzyme
was active even though it lacked PLA1 activity. Furthermore, using the Blue-Agarose
fraction rich in PLA1 activity we were unable to detect MGLL activity using this same
assay. These results suggested that MGLL does not have PLA1 activity and therefore is
unlikely to contribute to the production of LPA during blood coagulation.
We next tested whether LYPLA-I/APT1 functioned as a PLA1. Human
recombinant GST-LYPLA-I/APT1 was expressed and purified from transformed E.coli.
Coomassie Blue stained SDS-PAGE showed that the purified GST-tagged LYPLAI/APT1 and the LYPLA-I/APT1 with the GST-tag removed yielded a single protein band
with the expected 25 KDa size (Figure 2.3A). PLA1 activity assays using 1µg NBD-PC in
20µl 10mM TRIS (pH 7.9) at 37°C for 10min performed on GST-tagged LYPLA-I/APT1
and thrombin-cleaved LYPLA-I/APT showed no detectable PLA1 activity with GSTtagged enzyme (Figure 2.3B). In contrast, the LYPLA-I/APT1 with the tag removed
showed activity when incubated with NBD-PC indicating that the GST tag inhibits
activity of the enzyme and that LYPLA-I/APT1 possesses phospholipase A1 activity.
2.3.5 Recombinant Human LYPLA-I/APT1 Acts Primarily as a Phospholipase A1
and Does Not Break Down LPA
LYPLA-I/APT1 has two known functions to date. As an acyl-protein thioesterase
it has been shown to deacylate G proteins and other thioacylated protein substrates
(Duncan and Gilman, 1998). As a lysophospholipase it cleaves the remaining fatty acid
from either carbon of the glycerol backbone of lysophosphatidylcholine or
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Table 2.2 LC-MS/MS Candidate protein peptide sequences.
Protein name

Entry name

Accession
code

Lecithin-cholesterol
acyltransferase

LCAT_HUMAN

P04180

Lysophospholipase
A-I

LYPA1_HUMAN

Phosphatidyl-serine
specific PLA1
Monoglyceride
Lipase

Theoretical
molecular
weight
(kDa)
67

O75608

25

PLA1A_HUMAN

Q53H76

55

MGLL_HUMAN

Q99685

59

Peptide sequence*

Occurrence of
peptide found
in samples

DLLAGLPAPGVEVYC*L
YGVGLPTPR
TYSVEYLDSSK
SSGLVSNAPGVQIR
LDKPDVVNWM#C*YR
ITTTSPWMFPSR
TYIYDHGFPYTDPVGVL
YEDGDDTVATR
LAGVTALSC*WLPLR
ASFPQGPIGGANR
TYEGMMHSSC*QQEMM
DVK
TLVNPANVTFK
FC*TALLPVNDR
C*ADFQSANLFEGTDLK
LTVPFLLLQGSADR

3

* C* indicates carbamidomethylated cysteine. M# indicates oxidized methionine.

29

2
4
3
3
2
3
5
5
6
1
1
1

Figure 2.3 Human recombinant LYPLA-I/APT1 with and without a GST tag are
purified for analysis. Coomassie Blue stained SDS-PAGE gels show the protein profiles
of the GST tagged LYPLA-I/APT1 protein and the thrombin-cleaved LYPLA-I/APT1
protein (5µg each). Human recombinant LYPLA-I/APT1 must be unlabeled for
functionality (panel B). PLA activity assay was performed on both GST tagged LYPLAI/APT1 and thrombin-cleaved untagged LYPLA-I/APT1 (0.5µg each). No activity was
found when the GST tag was present. The thrombin-cleaved version of LYPLA-I/APT1
has abundant PLA1 activity when incubated with NBD-PC in the presence of BSA. Bars
are the mean of 3 independent determinations ± S.D.
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lysophosphatidylserine. Because this protein has lysophospholipase activity, it was
challenging to separate the PLA1 activity from the lysophospholipase activity as the
product of the PLA1 activity is also the substrate of the lysophospholipase activity. Using
unlabeled substrate to measure PLA1 activity of the recombinant enzyme was not
feasible, as we were unable to distinguish how much of the product was being cleaved by
the lysophospholipase activity precluding the determination of the specific PLA1 catalytic
activity. In order to establish a timeline for the dual activities of the same enzyme we
used NBD-PC, which allowed us to independently monitor the generation of NBD-LPC
(product of PLA1 cleavage) and NBD-FA (product of LYPLA-I/APT1 cleavage) products
for both enzymatic activities and at least initially monitor reaction preference. NBD-PC,
NBD-LPC, and NBD-FA were quantified as percentage of total substrate and product
(Figure 2.4A). Eleven percent of added NBD-PC was converted to NBD-LPC within
1min indicating the robust PLA1 activity of the enzyme. In contrast, NBD-FA production
reached a comparable amount, only after 5min of incubation, signifying further that the
initial and preferred product of LYPLA-I/APT1 was NBD-LPC. NBD-LPC reached a
maximum steady-state level of 25% after 5min, whereas NBD-FA generation continued
steadily with the availability of NBD-LPC substrate for the LYPLA-I/APT1 activity of
the enzyme. NBD-FA product could also be generated by PLA2 cleavage of NBD-PC;
however, this product was not seen initially making such catalytic activity unlikely.
Along with the generation of NBD-LPC and NBD-FA there was a continuous decrease in
the NBD-PC substrate. This time course is consistent with the hypothesis that human
recombinant LYPLA-I/APT1 acts preferentially as a PLA1 and only secondarily as a
LYPLA-I/APT1.
The hypothesis that LYPLA-I/APT1 would supply LPL to ATX and thereby
contribute to LPA production can only be sustained if LYPLA-I/APT1 would not cleave
LPA and degrade it. To test this hypothesis recombinant LYPLA-I/APT1 was incubated
with LPA 18:1 for up to 1 hour and the amount of LPA degraded was quantified by LCMS/MS (Figure 2.4B). The amount of LPA did not decrease during the 1-h-long
incubation indicating that LYPLA-I/APT1 is not a substrate for LYPLA-I/APT1 and
therefore, it does not contribute to the break-down of LPA.
2.3.6 LYPLA-I/APT1 Contributes to the Production of LPA during Blood
Coagulation
The predominance of 18:2 and 20:4 LPA species in serum indicate that PLA1
cleavage must be involved in this biochemical pathway because these fatty acids are
overwhelmingly esterified to the sn-2 carbon of phospholipids. ATX has low, but
constitutive activity for sn-1 LPC present in plasma indicated by the low concentration of
LPA and the rather slow increase in LPA in heparinized plasma ex vivo (Figure 2.5A &
2.5B) (Sano et al., 2002). Therefore, ATX alone cannot account for the upsurge in LPA
production subsequent to activation of blood clotting. We hypothesized that LYPLAI/APT1 release from activated platelets is, at least in part, responsible for the increase in
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Figure 2.4 Human recombinant LYPLA-I/APT1 acts first as a PLA1 then also has
lysophospholipase activity when incubated with NBD-PC. Purified human
recombinant LYPLA-I/APT1 was incubated with NBD-PC and BSA for 0, 1, 2.5, 5, 10,
20, and 30min (panel A). NBD-LPC is generated immediately indicating PLA1 activity of
the enzyme. After the initial generation of NBD-LPC, NBD-FA is generated indicating a
lysophospholipase activity of the enzyme with a simultaneous decrease in the starting
substrate. Human recombinant LYPLA-I/APT1 does not cleave LPA and therefore does
not contribute to the break-down of LPA (panel B). LYPLA-I/APT1 was incubated with
LPA 18:1 in the presence of BSA for 1 hour. The amount of LPA did not decrease during
incubation indicating that LPA is not a substrate for LYPLA-I/APT1. Bars are the mean
of 3 independent determinations ± S.D.
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LPA production by supplying a newly formed pool of LPL to ATX upon the activation of
platelets. To examine this, heparinized plasma and human activated plasma generated by
physiological means in venous blood were incubated with or without exogenously added
human recombinant LYPLA-I/APT1 for 24 hours and the production of polyunsaturated
LPA species was quantified using LC-MS/MS. Upon addition of LYPLA-I/APT1, LPA
18:2 (Figure 2.5A) and LPA 20:4 (Figure 2.5B) began increasing in a time-dependent
manner in physiologically-activated plasma. By the end of the 24-h incubation, addition
of LYPLA-I/APT1 to activated plasma significantly increased the amount of LPA 18:2
and 20:4. The generation of these LPA species in activated plasma without the addition
of LYPLA-I/APT1 also increased but to a much lower extent compared to the LYPLAI/APT1 spiked samples. It is important to note that these samples contain endogenous
LYPLA-I that also contributes to the production of LPC. There was no significant
increase in either LPA species when platelet activation was prevented by heparin and the
removal of plasma from the blood cells within 5min of blood collection. However, there
was a small increase at 24h with the addition of LYPLA-I/APT1 to heparinized plasma
suggesting the enzyme could utilize physiological substrates. We also determined that
heparin (18.75 U/mL) used for anticoagulation of blood inhibited 90% of the activity of
ATX although it did not inhibit the phospholipase A1 activity of LYPLA-I/APT1 (data
not shown).
To extend these observations we tested the effect of exogenous LYPLA-I/APT1
addition on LPA 18:2 and LPA 20:4 production in a small sample of human donors from
both sexes. Activated plasma was incubated with or without 10µg/mL human
recombinant LYPLA-I/APT1 for 24 hours and the amount of LPC 18:2, LPC 20:4, LPA
18:2 and LPA 20:4 was quantified using LC-MS/MS. LPC 18:2 (Figure 2.6C) increased
significantly by 1.5-fold with the addition of LYPLA-I/APT1 in contrast to a 1.3-fold
increase without LYPLA-I/APT1. Similarly, LPC 20:4 (Figure 2.6D) increased 2.8-fold
with the addition of LYPLA-I/APT1 and 2.5-fold without LYPLA-I/APT1. In the same
samples, LPA 18:2 (Figure 2.6A) increased 3.5-fold over 24h in comparison to 2.6-fold
without LYPLA-I/APT1. LPA 20:4 (Figure 2.6B) increased 4.6-fold without the addition
of LYPLA-I/APT1 relative to the level found at the beginning of the incubation and 5.8fold with the addition of LYPLA-I/APT1. The addition of LYPLA-I/APT1 significantly
increased (p<0.05 compared to time 0 analyzed by one-way ANOVA) the production of
polyunsaturated LPC and LPA indicating that this enzyme contributes to the production
of LPA during blood coagulation.
2.3.7 Regioisomeric Preference of ATX
To further understand the mechanism of LPA production upon blood coagulation
we wanted to determine the regioisomeric preference of ATX. We have determined that
LYPLA-I/APT1 cleaves phospholipids to yield sn-2 LPLs. These LPLs can either
undergo acyl migration and then be further cleaved by ATX to yield sn-1 LPA or the sn-2
LPLs can first be cleaved by ATX yielding sn-2 LPA that then undergoes acyl migration
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Figure 2.5 Human recombinant LYPLA-I/APT1 increases the amount of LPA 18:2
and LPA 20:4 in a time-dependent manner. Physiologically activated plasma and
plasma with heparin additive were incubated with or without human recombinant
LYPLA-I/APT1 for 24 hours. LPA 18:2 and LPA 20:4 in activated plasma began
increasing after 3 hours and increased greatly at 24 hours. In contrast, in heparinized
plasma LPA 18:2 and LPA 20:4 showed no increase except in the sample with LYPLAI/APT1 at 24 hours.

34

Figure 2.6 Human recombinant LYPLA-I/APT1 increases the amount of LPA
produced. The addition of LYPLA-I/APT1 increases the amount of LPA 18:2 (panel A),
LPA 20:4 (panel B), LPC 18:2 (panel C), and LPC 20:4 (panel D) produced in
physiologically activated plasma. Physiologically activated plasma was incubated with or
without human recombinant LYPLA-I/APT1 for 24 hours. LPA 18:2 and LPA 20:4
increased in 24 hours in comparison to the amount present in plasma immediately after
blood draw. Production of LPA and LPC substantially increased with the addition of
LYPLA-I/APT1 showing that LYPLA-I/APT1 plays a role in the production of LPA
during blood coagulation. These results are from 3 female donors and 4 male donors
(panel A, B & C) or 1 female donor and 3 male donors (panel D). Open symbols
represent female donors and closed symbols represent male donors (*p< 0.05 24 hour
activated plasma with LYPLA-I vs. without LYPLA-I analyzed by paired t-test).
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to form sn-1 LPA. Since the sn-2 regioisomer of LPC is relatively unstable (T1/2 ~ 30min
at pH 8.0), especially during incubation at 37°C (Pluckthun and Dennis, 1982) (acyl
migration generates a 9:1 excess of the sn-1 form), we were unable to use the natural
substrate for ATX to experimentally determine substrate preference. In order to prevent
acyl migration we used LPAF, an analogue of LPC in which the fatty acid is ether linked
to the glycerol backbone. Using an Amplex Red, fluorescence-based choline release
assay we determined the Km and Vmax of the sn-1 regioisomer to be 96 ± 10 µM and 0.11
± 0.003µM·min-1, respectively. In contrast, the Km and Vmax of the sn-2 regioisomer were
51 ± 4µM and 0.03 ± 0.004µM·min-1, respectively (Figure 2.7). The kcat value for the sn1 regioisomer was 11 ± 0.03min-1 whereas for the sn-2 regioisomer it was 3 ± 0.14min-1.
Km and kcat values help to assess the efficiency of the enzymes against a given substrate:
however, these values should not be used alone when considering the kinetic parameters
of an enzyme. To better compare the enzyme efficiency for the two substrates the ratio
kcat/Km (specificity constant) can be used. This provides a measure of catalytic efficiency
and allows for direct comparison of the efficiency of an enzyme towards different
substrates. The kcat/Km value for the sn-1 and sn-2 regioisomers of LPAF 18:1 were 0.12
± 0.01µM-1·min-1 and 0.05 ± 0.01µM-1·min-1 respectively (Table 2.3). Thus, the Kcat/Km
of the sn-1 regioisomer was 2.3 times higher than that of the sn-2 regioisomer indicating
that ATX catalyzes the sn-1 regioisomer of LPAF 18:1 more efficiently than the sn-2
regioisomer.
2.4 DISCUSSION
We have identified LYPLA-I/APT1 as an enzyme with PLA1 activity that is
released from human platelets during blood clotting that contributes to the generation of
polyunsaturated species of LPA abundant in serum. Since the early reports of
Schumacher et al. and Mauco et al. (Mauco et al., 1978; Schumacher et al., 1979) in the
late seventies, it has been known that platelet activation and LPA production are coupled,
however, the precise mechanism remained unknown (Eichholtz et al., 1993; Gaits et al.,
1997; Sano et al., 2002; Aoki et al., 2008). Previously we have shown that only trace
amounts of LPA are generated in activated platelets, far less than that could account for
the rise in LPA concentration from the nanomolar range in plasma to the several
micromolar level found in serum (Sano et al., 2002). The attention of the field has since
been focused on the hypothesis that activated platelets release phospholipases, which
generate a new pool of LPLs that are subsequently converted to LPA by ATX (Aoki et
al., 2002b; Sano et al., 2002). Because more than eighty percent of LPA in serum is
composed of the polyunsaturated 18:2 and 20:4 acyl species, we proposed that the LPL
pool accessed by the constitutive ATX in plasma is likely to be generated by PLA1
enzyme(s) derived from activated platelets (Sano et al., 2002). In pursuit of this
hypothesis in the present study we report on the identification of one such PLA1 enzyme
previously known as LYPLA-I/APT1, which contributes to the increase in LPA
production during blood coagulation. Even though our results suggest that this PLA1 is a
major contributor to the increase in LPA production, it may not be the only contributing
phospholipase released by activated human platelets.

36

Figure 2.7 Comparison of the cleavage of sn-1 with sn-2 LPAF 18:1 by ATX. A
linear segment of time vs. amount of product was plotted for each substrate concentration
(31.25µM – 2mM) to determine initial velocity. Substrate concentration vs. initial
velocity was plotted. All absorbance values were converted to µM resorufin produced to
report as actual product. Bars are the mean of 3 independent determinations ± SEM.

37

Table 2.3 Kinetic parameters for ATX-mediated hydrolysis of LPAF 18:1.
LysoPAF

Km (µM)

Vmax (µM·min-1)

Kcat (min-1)

sn-1

96 +/- 10

0.11 +/- 0.003

11 +/- 0.03

Kcat/Km (µM1
·min-1)
0.12 +/- 0.01

sn-2
51 +/- 4
0.025 +/- 0.004
n=3, average values +/- standard error.

3.0 +/- 0.1

0.050 +/- 0.01
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Previous studies have used fluorescent phospholipids or [32P]-orthophosphate for
biosynthetic labeling of the substrates to monitor platelet-derived phospholipases (Sano et
al., 2002). We developed LC-MS/MS techniques to monitor the sequential cleavage of
PC/PS to LPC/LPS to LPA without the use of unnatural, fluorescently labeled substrates.
Sano et al. previously showed that when fluorescently labeled PC, PE, or PS was
incubated with supernatant from thrombin-stimulated platelets no LPA production could
be detected. However, when plasma or serum was added LPA generation commenced
suggesting that elements of the biochemical pathway were missing from the platelet
supernatant (Sano et al., 2002). Using our newly developed method we were able to
directly demonstrate that ATX addition to platelet supernatant significantly increases
LPA production indicating that there is de novo generation of ATX substrates within the
platelet supernatant. Using sn-2 NBD-labeled PC and PS, we found overwhelming
hydrolytic activity generating NBD-LPC/LPS consistent with the abundant presence of
PLA1 activity in the platelet supernatant. Under these conditions we found much less
NBD-FA generation from either NBD-labeled phospholipid substrate, indicating that
PLA2 activity was lower than corresponding PLA1 activity toward these substrates. In the
absence of exogenously added recombinant ATX, although very little, more LPA was
generated from PS than from PC. This may indicate that some LPLD enzymes are present
in the supernatant that prefer LPS over LPC or that trace amounts of contaminating ATX
from plasma was present in the supernatant. It is also possible that the NBD-labeled
lipids are poor substrates for ATX, but are good substrates for LYPLA-I. Lastly, it is
known that LYPLA-I/APT1 is a multifunctional enzyme and cleaves LPC as a
lysophospholipase as well as PC as a phospholipase. Thus, the lysophospholipase activity
could have consumed LPC more readily than LPS, diminishing the former substrate from
ATX, thereby decreasing the amount of LPA produced.
Pamuklar and colleagues (Pamuklar et al., 2009) examined the interaction of
ATX with β3 integrin expressed on platelets and proposed that this mechanism could
localize and augment LPA production at the surface of platelets. We did not detect
substantial LPA production by activated purified human platelets in the absence of added
ATX (Figure 2.1). Thus, it appears that little ATX is associated with non-activated
circulating human platelets and activation of β3 integrins is required for capturing ATX
to the platelet surface. Whether LPA receptors expressed in platelets activate β3
integrins thereby promoting ATX binding remains to be demonstrated. Such feedforward mechanism amplifying LPA production at the platelet surface and aggregation
via LPA receptors could play a role in thrombosis and hemostasis.
In the present study using three sequential chromatographic steps we were unable
to purify the PLA1 activity to homogeneity. We pursued an affinity-labeling strategy
using a fluorophosphonate probe, which selectively reacts with serine residues in the
catalytic site of serine hydrolases to which most lipases belong (Leung et al., 2003).
Using the FP-Biotin-labeled serine hydrolases isolated from the partially-purified PLA1
fraction, we applied LC-MS/MS in combination with database searches to identify these
enzymes. We searched for proteins that were known lipases among the FP-Biotin-labeled
proteins. Most lipase domain members have characteristic surface loops (β9 loops) and a
lid domain (Aoki et al., 2002a). These loops are part of the active site and help determine
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substrate recognition. These domains helped to identify our protein of interest. We also
ignored all proteins that were too large to fit the size of the PLA1 estimated by gel
filtration (25KDa and 50KDa - data not shown) and excluded any unknown peptide
sequences. Using these exclusion criteria, we identified four proteins that were potential
candidates for a PLA1. We further reasoned that if the PLA1 is released from platelets
then it should be synthesized in platelets. Therefore, we looked for RNA transcripts of the
four lipases in platelets. Using this criterion we were able to eliminate LCAT and PSPLA1, leaving MGLL and LYPLA-I/APT1 as the two remaining candidates.
We were also able to eliminate MGLL as a potential candidate protein because
the recombinant enzyme lacked PLA1 activity. We next cloned and expressed the human
LYPLA-I/APT1 and unexpectedly found that the GST-tag interfered with enzymatic
activity. We do not know whether the GST tag may have interfered with protein folding
or may have affected the ability of the substrate to bind to the enzyme. Despite this
interference, once the GST tag was removed, we determined that the recombinant
LYPLA-I/APT1 had PLA1 activity against NBD-labeled and natural PC or PS. Our
attempts to determine the Km value of LYPLA-I/APT1 with PC or PS substrates were
unsuccessful because the product of PLA1 cleavage is also the substrate of the
lysophospholipase activity of the enzyme. LYPLA-I/APT1 has been shown to cleave
fatty acids esterified to either the sn-1 or the sn-2 carbon of LPC (Wang et al., 1997).
However, we determined that LPA was not cleaved by LYPLA-I/APT1 indicating that
this product escapes further modification by this multifunctional enzyme.
Another function of LYPLA-I/APT1 is the deacylation/depalmitoylation of G
proteins, ghrelin, and other thioacylated protein substrates (Duncan and Gilman, 1998;
2002; Hirano et al., 2009; Satou et al., 2010). Deacylation/depalmitoylation contributes
to the regulation of lipid modifications and reverses the process of thioacylation of
proteins involved in signal transduction. It has been shown that the Km of the
lysophospholipase activity is about 8-times higher than the Km value of the thioesterase
activity of the enzyme. The Vmax is also about 17 times lower for the lysophospholipase
activity than the thioesterase activity (Hirano et al., 2009). Based on these data it has
been proposed that LYPLA-I/APT1 has a much higher thioesterase activity than
lysophospholipase activity. However, in vivo the activity of this enzyme is likely to be
affected by the availability and presentation of the different substrates.
In order to make a distinction between substrate preference for PC and LPC of
LYPLA-I/APT1, we used NBD-PC substrate and followed the time course of NBD-LPC
production generated by the PLA1 activity and NBD-FA production generated through
lysophospholipase activity. We observed a considerable delay in the formation of NBDFA relative to NBD-LPC, the latter being continuously generated. For this reason, we
suggest that LYPLA-I/APT1 functions preferentially as a PLA1 and only after the buildup of LPL concentration presumably via acyl migration it begins to cleave this substrate
as a lyso-PLA1.
Without a knockout animal model or specific inhibitors of LYPLA-I/APT1 we
were limited to study the effect of the enzyme on ex vivo LPA production in activated
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plasma. Following the addition of LYPLA-I/APT1 to heparinized plasma, we detected
only a very small increase in polyunsaturated LPA production at 24h suggesting that the
enzyme can utilize physiological substrates. However, this increase was confounded
because heparin inhibited the activity of ATX but not the PLA1 activity of LYPLAI/APT1. LPA production in activated plasma began to increase after 3 hours and
continued up to 24 hours (the last time point tested). Spiking LYPLA-I/APT1 into
activated non-anticoagulated plasma increased LPA 18:2 and 20:4 production by 5- and
4-fold, respectively. This augmentation of LPA production indicates that LYPLA-I/APT1
recognizes and cleaves plasma phospholipids and contributes to the generation of LPA
during blood coagulation. Production of LPA by this pathway is limited by the amount of
LYPLA-I/APT1 released from platelets and the rate with which ATX generates LPA
relative to the rate with which LYPLA-I/APT1 degrades LPL.
We considered that LYPLA-I/APT1 generates a new pool of sn-2 LPL, which can
potentially undergo acyl migration before or after headgroup cleavage by ATX. The sn-2
regioisomer of LPC is relatively unstable and undergoes acyl migration to the sn-1
position at neutral pH at 37°C. Due to the several minute-long half-life of the sn-2
regioisomer (Pluckthun and Dennis, 1982) we were unable to obtain biochemical proof
whether the nascent LPA generated is of the sn-2 or sn-1 regioisomer because the
extraction and HPLC separation of the regioisomers takes longer than 30 minutes. To
obtain indirect insight into the role of acyl migration on ATX cleavage, we synthesized
the sn-2 regioisomer of LPAF and compared its cleavage with the sn-1 regioisomer. ATX
cleaved the sn-1 LPAF with a higher kcat/Km than its sn-2 counterpart. Based on this
finding it seems logical to propose that acyl migration occurs predominantly at the LPL
stage of this biochemical pathway. However, only direct measurement of the nascent LPL
and LPA regioisomers can help settle this question. An additional factor that must be
taken into consideration is the short half-life of LPA in blood in vivo. LPA appears to be
continuously produced and simultaneously broken down in blood on the minute scale
(Albers et al., 2010). This might create a situation that may enrich the abundance of sn-2
regiosomer in blood relative to the sn-1 regioisomer because the LPA generated is broken
down before or at a similar rate with which acyl migration occurs.
Based on the results of this study, we hypothesize that LPA production during
blood coagulation occurs via the following steps: 1) Upon activation platelets release
LYPLA-I/APT1. 2) LYPLA-I/APT1 cleaves phospholipids to generate a new pool of sn2 LPL. 3) These newly generated sn-2 LPLs undergo acyl migration within minutes to
produce a pool of sn-1 LPLs. 4) ATX or other lysophospholipase D enzymes cleave the
sn-1 LPLs to generate an upsurge of sn-1 LPA enriched in polyunsaturated FA. This
hypothesis needs further testing and the availability of LYPLA-I/APT1 knockout animals
and rapid methods for the detection of LPA and LPA regioisomers will accelerate the
progress toward a better understanding of LPA production in biological fluids.
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2.5 SUPPLEMENTAL INFORMATION
Synthesis and characterization of sn-2 lyso-PAF 18:1.
2-Oleyl-sn-glycero-3-phosphocholine (1) was synthesized. The synthetic scheme
began with 3-O-(4-Methoxybenzyl)-sn-glycerol (2), which contains the appropriate
stereochemistry for the subsequent target product and was synthesized as previously
described (Perly et al., 1984; Rowland and Best, 2009). First, the primary alcohol of diol
2 was selectively protected through reaction with tert-butyldiphenyl chlorosilane to
produce compound 3. Next, ether bond formation using oleyl triflate was performed to
afford fully protected glycerol 4, followed by deprotection of the p-methoxybenzyl
(PMB) group to provide the free alcohol of 5. Phosphoramidite chemistry was then used
to install the choline phosphodiester of 7, at which time it was found that the cyanoethyl
protecting group on the phosphate was deprotected in situ. When followed by mass
spectrometry, this was found to happen during the process of purifying compound 7. The
yield for the 2-step production of 7 is somewhat low, likely due to the challenges
associated with forming mixed phosphodiesters and the purification of the lyso-lipid
product. Finally, the removal of the silyl protecting group of 7 yielded LPC analog 1. It
is worth mentioning that a similar approach was also pursued that involved a glycerol
precursor with opposite stereochemistry, initial removal of the silyl group, and
deprotection of the PMB in the final step. However, this alternative route led significant
challenges in purifying the final product, and was thus abandoned in favor of the route
described above. LPC analog 1 has previously been reported in enantiomerically pure
(Hirth et al., 1983) as well as racemic form (Huang et al., 2006) using different synthetic
routes.
3-O-(4-Methoxybenzyl)-1-O-(tert-Butyldiphenylsilyl)-sn-glycerol (3) Diol 2 was
synthesized from S-glycerol acetonide (purchased from AK Scientific, Inc.) according to
a known procedure (Perly et al., 1984; Rowland and Best, 2009). Diol 2 (0.430g,
2.026mmol) was then dissolved in dry N,N-dimethylformamide (20ml), to which was
added tert-butyldiphenyl chlorosilane (0.525ml, 2.026mmol), followed by imidazole
(0.359g, 5.270mmol). The reaction mixture was next allowed to stir at room temperature
overnight. The solvent was then concentrated under reduced pressure and the resulting
residue was dissolved in chloroform (100ml) and washed with water (2 x 50ml). The
organic layer was then dried with magnesium sulfate and the solvent evaporated to yield
the crude product. Purification via column chromatography with silica gel and gradient
elution with 15–35% ethyl acetate/hexanes yielded 3 as a colorless oil (0.73g, 80%). The
product matched previous characterizations (Greimel et al., 2008). 1H NMR (300 MHz,
CDCl3): δ 7.62–7.65 (d, J=9.0 Hz, 4H), 7.34–7.42 (m, 6H), 7.20-7.25 (m, 2H), 6.84-6.87
(d, J=9.0 Hz, 2H), 4.45 (s, 2H), 3.88–3.92 (m, 1H), 3.79 (s, 3H), 3.69–3.71 (d, J=6.0 Hz,
2H), 3.50-3.54 (m, 2H), 2.47 (d, J=6.0 Hz, 1H), 1.06 (s, 9H); MALDI-HRMS [M+Na]+
calcd: 473.2119, found: 473.2093.
1-O-(tert-Butyldiphenylsilyl)-2-oleyl-3-O-(4-Methoxybenzyl)-sn-glycerol (4) The
procedure for synthesis of 4 was modified from similar ether-tail forming reactions (Jiang
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et al., 2006). Compound 3 (0.660g, 1.465mmol) was dissolved in dry dichloromethane
(40ml), to which was added 1,8-Bis(dimethylamino)naphthalene (proton sponge, 1.10g,
5.15mmol) and oleyl triflate (2.900g, 7.240mmol), which was prepared from a known
procedure (Heyes et al., 2002). The solution was next heated to reflux and allowed to stir
overnight. The solvent was then removed under reduced pressure to yield the crude
product 4, which was purified by column chromatography with silica gel and gradient
elution with 5–10% acetone/hexanes to yield 4 as a yellowish oil (0.714 g, 71%). 1H
NMR (300 MHz, CDCl3): δ 7.66–7.75 (m, 4H), 7.32–7.40 (m, 6H), 7.22-7.30 (m, 2H),
6.83-6.91 (m, 2H), 5.35-5.41 (m, 2H), 4.47-4.52 (m, 2H), 3.79 (s, 3H), 3.38 -3.70 (m,
7H), 2.04 (m, 4H), 1.58 (m, 2H), 1.30-1.36 (m, 22H), 1.03-1.06 (m, 9H), 0.90-0.94 (m,
3H); 13C NMR (100.6 MHz, CDCl3): δ 159.14, 135.99, 135.64, 133.57, 129.90, 129.48,
129.21, 129.13, 127.66, 127.43, 113.69, 113.59, 79.48, 73.02, 71.38, 69.71, 63.50, 55.16,
32.70, 31.99, 30.18, 29.78, 29.72, 29.58, 29.33, 26.20, 22.76, 19.25, 14.21; MALDIHRMS [M+Na]+ calcd: 723.4779, found: 723.4759.
1- O-(tert-Butyldiphenylsilyl)-2-oleyl-sn-glycerol (5) Compound 4 (0.325g,
0.463mmol) was combined with 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ, 0.315g,
1.389mmol) in dichloromethane (10ml) and water (1ml). The reaction mixture was then
stirred at rt. After 10h, saturated sodium bicarbonate (100ml) was added to quench the
reaction, and the resulting solution was then extracted twice with chloroform (2 x 100ml).
The organic layers were then combined and dried with magnesium sulfate and the solvent
removed by rotary evaporation to yield the crude product, which was carried on to the
next step without further purification.
1-O-(tert-Butyldiphenylsilyl)-2-oleoyl-sn-glycero-3-phosphocholine (7) Crude
compound 5 was combined with bis-(N,N-diisopropylamino) cyanoethyl phosphine (6,
0.205g, 0.606mmol), and 1H-tetrazole (0.740ml of a 0.45M solution in acetonitrile,
0.333mmol) in dichloromethane (10ml), and the solution was allowed to stir at rt for 1h.
To this stirred solution, choline tosylate (0.334g, 1.212mmol), and 1H-tetrazole (2.690ml
of a 0.45M solution in acetontrile, 1.212mmol) were added, and the solution was allowed
to stir at rt for another 12h, after which tert-butylhydroperoxide (0.470ml, 4.848mmol)
was added. After 1h, the reaction was quenched by adding 50ml of saturated sodium
thiosulfate aqueous solution. Next, the resulting solution was extracted with
methanol/methylene chloride (v/v 1:4, 2 x 80ml), and the organic layers were combined
and dried with magnesium sulfate. The solvent was then removed under reduced
pressure, and the resulting residue was purified by column chromatography with silica
gel through gradient elution of 5–30% methanol/dichloromethane to yield 7 as a colorless
oil (0.060 g, 17 % yield over 2 steps). 1H NMR (300 MHz, CDCl3): δ 7.65–7.69 (m, 4H),
7.26–7.38 (m, 6H), 5.32-5.35 (m, 2H), 4.14-4.18 (m, 2H), 3.89-3.91 (m, 2H), 3.49-3.74
(m, 5H), 3.28-3.30 (m, 2H), 3.22 (s, 9H), 1.99-2.01 (m, 4H), 1.47-1.49 (m, 2H), 1.191.23 (m, 22H), 1.02 (s, 9H), 0.86 (t, J=6.0 Hz, 3H); 31P NMR: δ −0.59; MALDI-HRMS
[M-H]+ calcd: 746.4939, found: 746.4946.
2-Oleyl-sn-glycero-3-phosphocholine (1) Compound 7 (0.060g, 0.080mmol) and
tetrabutylammonium fluoride trihydrate (TBAF, 0.126g, 0.40mmol) were dissolved in
tetrahydrofuran (10ml), and the reaction was allowed to stir at room temperature
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overnight, at which point the solvent was removed under reduced pressure. Purification
of the resulting residue by column chromatography with 3 g of silica gel and a gradient
eluant of 10–50% methanol/chloroform yielded 7, but also contained TBAF as a
contaminant. This mixture was then dissolved in water and stirred with Chelex-100 resin,
sodium form, for 3h. The solution was then loaded directly onto a C18 reverse phase
column and eluted with a gradient of water/methanol mixtures to yield 7 as an off-white
paste (0.025g, 62%). The product matched previous characterizations.(Hirth et al., 1983;
Huang et al., 2006) 1H NMR (300 MHz, CD3OD/CDCl3, v/v 1:2): δ 5.33-5.36 (m, 2H),
4.4-4.28 (m, 2H), 4.14 (m, 1H), 3.96 (t, J=6.0 Hz, 2H), 3.49-3.74 (m, 5H), 3.34-3.36 (m,
2H), 3.21 (s, 9H), 1.99-2.04 (m, 4H), 1.52-1.59 (m, 2H), 1.25-1.32 (m, 22H), 0.86 (t,
J=6.0 Hz, 3H); 31P NMR: δ 4.01; MALDI-HRMS [M-H]+ calcd: 508.3762, found:
508.3768.
Column chromatography was performed using 230–400 mesh silica gel purchased
from Sorbent Technologies (Atlanta, GA). NMR spectra were obtained using a Varian
Mercury 300 spectrometer. Mass spectra were obtained with a Voyager DE MALDI-TOF
spectrometer. Synthesis of 2-Oleyl-sn-glycero-3-phosphocholine (1) is shown in Scheme
2.1.
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Scheme 2.1 Synthesis of 2-oleyl-sn-glycero-3-phosphocholine.
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CHAPTER 3. QUANTIFICATION OF SN-1 AND SN-2 REGIOISOMERS OF
LPA AND LPC
3.1 INTRODUCTION
We hypothesized that the production of sn-1 LPA during blood coagulation
proceeds through the following steps: 1) Secretion of PLA1 from activated platelets. 2)
Generation of sn-2 LPLs by PLA1. 3) Acyl migration of sn-2 LPLs to yield the sn-1
regioisomer of LPLs. 4. Cleavage of sn-1 lysophospholipids by LPLD to yield sn-1 LPA.
The predominance of 18:2 and 20:4 LPA species in serum indicate that PLA1 cleavage
must be involved in this biochemical pathway because these fatty acids are only present
in the sn-2 position of phospholipids. In order to understand LPA production in biological
fluids we sought to develop a method for the separation and quantification of the sn-1 and
sn-2 regioisomers of LPC and LPA. Using such a method one would be able to analyze
human blood samples at various time points throughout the coagulation process and
accurately determine a time course of the production of sn-2 and subsequently sn-1
lysophospholipids. We have developed an HPLC method coupled with MS/MS that
separated the regioisomers of both LPC and LPA. However, the duration of the
extraction and separation of the regioisomers (~40 min) was longer than the very short
half-life (~10 min) of the sn-2 regioisomer in biological samples (Pluckthun and Dennis,
1982). Consequently, were unable to reliably resolve any changes in the composition of
the sn-1 and sn-2 regioisomers in human plasma or blood samples using this method.
3.2 METHOD DEVELOPMENT
3.2.1 Production of the sn-2 Regioisomer of LPC and LPA
sn-2 LPA 18:2 standard was synthesized from dilinoleoyl-phosphatidic acid (18:2
PA) using Rhizomucor miehei lipase specific for fatty acid esters in positions 1 and 3 on
the glycerol backbone (Sigma-Aldrich, St. Louis, MO). 400 µg PA 18:2 was incubated
at 37˚ C for 1h in 100µl reaction buffer (10mM TRIS, pH 7.8,150mM NaCl, and 2mM
CaCl2 final concentration) with 500µl lipase (10 units) and an equal volume of diethyl
ether. The aqueous phase was then transferred to a new glass tube and 200µl watersaturated butanol was added. The sample was vortexed and centrifuged for 1min at 13000
x g,and the butanol layer was isolated and dried under a stream of argon gas.
sn-2 LPC 18:1 was synthesized from PC 16:0-18:1 using Rhizopus arrhizus
miehei lipase. 400 µg PC 18:1 was incubated at 37˚ C for 1h in 100µl reaction buffer
(10mM TRIS, pH 7.8, 10mM TritonX-100 final concentration) with 10µg lipase (0.1
units). The product was extracted using the same procedure described above for sn-2
LPA.
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3.2.2 LC-MS/MS Method Development for Separation of the sn-1 and sn-2
Regioisomers of LPA
We used a Tosoh TSK-ODS-100Z column (250mm x 2 mm; silica with 5-µm
particle size) HPLC column to separate sn-1 and sn-2 regioisomers of LPA. The HPLC
column was connected to a Shimadazu LC-10ADvp pump (Columbia, MD) and
interfaced to an Applied Biosystems Sciex (Foster City, CA) API 4000 tandem mass
spectrometer equipped with a TurboionsprayTM interface. The typical ion source
parameters used were: Capillary 3.5 kV, declustering potential (DP) 32 V, focusing
potential (FP) 130 V, entrance potential (EP) -12 V, collision energy (CE) 29 eV,
collision cell exit potential (CXP) 10 V, deflector -348 V, channel electron multiplier
(CEM) 2200 V, and source temperature 325˚C. The data was processed by Analyst
software, version 1.3. Various species of LPA were analyzed by multiple reaction
monitoring (MRM) in negative ion mode with Q3 (product ion) set at m/z 153
(glycerophosphate moiety). LPC species were analyzed in MRM positive ion mode with
Q3 set at m/z 184 (glycerophosphocholine). Q1 was set for the deprotonated molecular ion
for all lysophospholipids (Tokumura, 2009).
Since commercially available sn-1 LPA contains some sn-2 regioisomers, we
started method development by separating sn-1 and sn-2 regioisomers present in 5ng
LPA 20:0 and 18:1 purchased from Avanti Polar Lipids (Alabaster, AL). Our goal was to
obtain baseline separation for multiple LPA species. Initially we used a 150 mm Tosoh
TSK-ODS-100Z column (2 mm diameter; 5-µm particle size) and methanol/water (95/5,
v/v) containing 5mM ammonium formate as the mobile phase with an isocratic flow rate
of 0.22 ml/min. LPA 20:0 was reconstituted in the mobile phase for injection. The
separation of the regioismers of LPA 20:0 was incomplete (Figure 3.1A). The sn-1 peak
retention time was 5.6 min and the sn-2 peak retention time was 5.3 min. To improve the
separation, LPA was reconstituted in acetonitrile/methanol/isopropanol/water (1/1/1/1,
v/v) for injection. The separation improved slightly but baseline separation could not be
achieved (Figure 3.1B). From this point on all samples were injected in
acetonitrile/methanol/isopropanol/water (1/1/1/1, v/v) solvent.
Next, we adjusted the concentration of water in the mobile phase because
increasing water concentration slows elution time and improved the separation of the
regioisomers. We increased water to 7.5% V/V that improved peak separation of the LPA
20:0 sn-1 and sn-2 regioisomers to 0.7 min (Figure 3.1C). To further increase separation
we changed the mobile phase to methanol/water (90/10, v/v) containing 5mM ammonium
formate. The peak separation of the LPA 20:0 regioisomers increased to 1.28 min, but the
separation of the LPA 18:1 regioisomers remained 0.60 min and poor (Figure 3.2). To
increase the separation of all major acyl species we adjusted the column temperature
from 40 ˚C to room temperature, which further improved the separation (data not shown).
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Figure 3.1 HPLC-MS/MS chromatogram of LPA 20:0 regioisomers under varying
conditions. LPA 20:0 injected in methanol/water (95/5, V/V), 5mM ammonium formate
solvent and mobile phase (panel A). LPA 20:0 injected in acetonitrile/methanol
/isopropanol /water (1/1/1/1, V/V/V/V) solvent and methanol/water (95/5, V/V), 5mM
ammonium formate mobile phase (panel B). LPA 20:0 injected in acetonitrile/methanol/
isopropanol/water (1/1/1/1, V/V/V/V) solvent and methanol/water (92.5/7.5, V/V), 5mM
ammonium formate mobile phase (panel C).
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Figure 3.2 HPLC-MS/MS chromatogram of LPA 18:1 and 20:0 regioisomers. LPA
18:1 and 20:0 injected in acetonitrile/methanol/isopropanol/water (1/1/1/1, V/V/V/V)
solvent and methanol/water (90/10, V/V), 5mM ammonium formate mobile phase.

49

To validate the method for the most abundant polyunsaturated LPA species we
synthesized LPA 18:2 regioisomers and injected nominally equal amounts of the sn-1 and
sn-2 regioisomers. In the commercially available LPA 18:2 (Avanti, Alabaster, AL) the
peak retention times were 8.3 and at 9.2 min for the sn-2 and sn-1 regioisomers,
respectively (Figure 3.3A). The synthetic sn-2 LPA when injected alone showed a peak
retention time at 8.4 min (Figure 3.3B). The mixture of the two regioisomers showed a
peak retention time of 8.1 min for the sn-2 and 9.2 min for the sn-1 providing validation
of the identity of the peaks detected in the commercial LPA 18:2 preparation (Figure
3.3C). Because of the large tail of the sn-2 peak, small amounts of sn-1 LPA could not be
resolved. Because of this we decided to further improve the separation of the
regioisomers by increasing the water concentration to 20% and found that this resulted in
a separation of the two peaks by 3.4 min (Figure 3.4). The retention times of the various
LPA and LPC species under varying conditions are summarized in Table 3.1.
3.2.3 Stability of the sn-2 Regioisomers of LPA and LPC
Based on studies conducted with LPC, it has been widely accepted that the sn-2
regioisomers of lysophospholipids are highly unstable and that acyl migration towards a
9:1 equilibrium ratio of sn-1 to sn-2 occurs rapidly in aqueous buffers in a pH dependent
manner (Pluckthun and Dennis 1982). Pluckthun and Dennis showed that the rate of acyl
migration increases as pH increases. They also showed that acyl migration is reduced at
pH 4.0 to 5.0 but again increases as pH decreases from 4.0 to 1.0. Pluckthun and Dennis
used 31P NMR to show that upon synthesis of sn-2 LPC 16:0 acyl migration begins to
take place immediately and within 60 minutes more than 60% of the sn-2 LPC 16:0 has
migrated to the sn-1 position (Pluckthun and Dennis 1982).In order to gain confidence in
our method of quantification of the sn-1 and sn-2 regioisomers of LPC and LPA, it was
imperative that we determine the stability of the sn-2 regioisomer under the conditions
used in our method. To achieve this, sn-2 LPA 18:2 was synthesized as described above
and divided into two samples. The first sample was reconstituted in
isopropanol/water/methanol/acetonitrile (1/1/1/1, V/V/V/V) and immediately analyzed by
LC-MS/MS with a mobile phase of methanol/water (90/10, v/v) 5mM ammonium
formate (Time 0, Figure 3.5A). This sample was then left at room temperature and
reanalyzed by LC-MS/MS at 1 hour and 24 hours later (1 hour at pH 4.0, Figure 3.5B; 24
hour at pH 4.0, Figure 3.5C). It was determined that the sn-2 regioisomer was stable at
pH 4.0 for at least 24 hours of incubation and no migration occurred throughout the time
and conditions of the mass spec method for analysis. We also tested the stability of the
sn-2 regioisomer of LPC 18:1. sn-2 18:1 LPC was prepared from 16:0-18:1 PC as
previously described. The sample was reconstituted with 20µl
isopropanol/water/methanol/acetonitrile (1/1/1/1, V/V/V/V) and immediately analyzed
using LC-MS/MS (Figure 3.6A). The sample was left at room temperature for 24 hours
and reanalyzed (Figure 3.6B). sn-1 and sn-2 18:1 LPC was also analyzed to validate
retention times (Figure 3.6C). Based on these experiments we can conclude that the sn-2
regioisomer of LPC 18:1 is stable under the conditions used for analysis.
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Figure 3.3 HPLC-MS/MS chromatogram of LPA 18:2 regioisomers. sn-1 LPA 18:2
(panel A), sn-2 LPA 18:2 (panel B), and sn-1 and sn-2 LPA 18:2 (panel C) injected in
acetonitrile/methanol/isopropanol/water (1/1/1/1, V/V/V/V) solvent and methanol/water
(90/10, V/V), 5mM ammonium formate mobile phase.
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Figure 3.4 HPLC-MS/MS chromatogram of separation of LPA 18:2 regioisomers.
sn-1 and sn-2 LPA 18:2 injected in acetonitrile/methanol/isopropanol/water (1/1/1/1,
V/V/V/V) solvent and methanol/water (80/20, V/V), 5mM ammonium formate mobile
phase.
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Table 3.1 Retention times of LPA and LPC species under varying conditions.
Ratio of
sn-1
sn-2
methanol/water retention retention
(V/V) in
time
time
Mobile Phase*
(min)
(min)
95/5
5.6
5.3

LPA/LPC
species

Solvent

LPA 20:0

Methanol/water 95/5
(V/V) 5mM
ammonium formate

LPA 20:0

acetonitrile/methanol/
isopropanol/water
(1/1/1/1, v/v)

95/5

5.5

5.1

0.4

LPA 20:0

acetonitrile/methanol/
isopropanol/water
(1/1/1/1, v/v)

92.5/7.5

8.4

7.7

0.7

LPA 20:0

acetonitrile/methanol/
isopropanol/water
(1/1/1/1, v/v)

90/10

13.4

12.1

1.3

LPA 18:2

acetonitrile/methanol/
isopropanol/water
(1/1/1/1, v/v)

90/10

9.2

8.3

0.9

LPA 18:2

acetonitrile/methanol/
isopropanol/water
(1/1/1/1, v/v)

80/20

28.7

25.3

3.4

LPC 18:1

acetonitrile/methanol/
isopropanol/water
(1/1/1/1, v/v)

90/10

39.2

33.3

5.9

61.1

51.1

10.0

LPC 18:1

acetonitrile/methanol/
80/20
isopropanol/water
(1/1/1/1, v/v)
*Mobile phase includes 5mM ammonium formate.
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Peak
separation
(min)
0.3

Figure 3.5 HPLC-MS/MS chromatogram of sn-2 LPA 18:2 at varying time points
post synthesis. sn-2 LPA 18:2 injected in acetonitrile/methanol/isopropanol/water
(1/1/1/1, V/V/V/V) solvent and methanol/water (90/10, V/V), 5mM ammonium formate
mobile phase at time 0 (panel A), 1 hour at pH 4.0 (panel B), and 24 hours at pH 4.0
(panel C).
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Figure 3.6 HPLC-MS/MS chromatogram of sn-2 LPC 18:1 at varying time points
post synthesis. sn-2 LPC 18:1 injected in acetonitrile/methanol/isopropanol/water
(1/1/1/1, V/V/V/V) solvent and methanol/water (80/20, V/V), 5mM ammonium formate
mobile phase at time 0 (panel A), 24 hours at pH 4.0 (panel B), time 0 sn-1 and sn-2 LPC
18:1 (panel C).
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3.2.4 Application
In order to quantify the various regioisomers at different time points in human
serum, 5ml blood was drawn into a heparinized or non-treated Vacutainer tubes. Blood
was centrifuged at 14000 x g for 1min and the PRP was transferred to a new tube. The
PRP from the tube with no additive was allowed to clot to generate serum. 1 ml aliquots
of plasma and serum incubated for 1 hour and 24 hours at 37°C were spiked with 50ng
LPA 17:0 internal standard. LPA and LPC were extracted as described by Bollinger, et
al. (Bollinger, Ii et al. 2010). High yield extraction of lipids from biological samples is
difficult. Bollinger et al. have recently developed a method of extraction that has been
shown to be cleaner and higher yield than previous methods. Regioisomers of LPA 18:2
and LPC 18:1 and 18:2 were analyzed using the appropriate m/z ratios of the
regioisomers at the proper retention times. To minimize run time a mobile phase of
methanol/water (90/10, v/v) 5mM ammonium formate was used for analysis of LPC
species. The ratio of sn-1 to sn-2 LPC 18:1 and 18:2 was 9:1 in all plasma and serum
samples (Figure 3.7A, B, and C). We expected this ratio in plasma however; we expected
an immediate but short lived spike in the sn-2 regioisomers in serum incubated for 1
hour. The same 9:1 ratio was found for the sn-1 and sn-2 regioisomers of LPA 18:2 in all
samples (Figure 3.8A, B, and C).
3.2.5 Conclusions
We have developed a HPLC/MS/MS method for the detection and quantification
of LPA and LPC sn-1 and sn-2 regioisomers. Using this method we will be able to further
progress toward a more complete analysis of LPA production in biological fluids. We
were unable to observe a change in the composition of the regioisomers in human plasma
or serum using the extraction method described by Bollinger et al. (Bollinger, Ii et al.
2010). Even though this method was designed to limit the acidification of the sample, it is
possible that the extraction method encouraged acyl migration towards equilibrium with
the minimal acidic nature of the extraction. This extraction method is also quite long (~1
hour to complete) which may have allowed time for acyl migration. In order to observe
the sn-2 regioisomer production and migration a much more rapid method of lipid
extraction from biological samples must be developed in which the samples are at a
constant pH range of 4.0 to 5.0 to minimize any pH dependent acyl migration.
Using this method in conjunction with a rapid lipid extraction into a slightly
acidic solvent (pH 4.0-5.0), one can potentially analyze the composition of all species of
sn-1 and sn-2 LPC and LPA at different time points during blood coagulation and
determine changes in the regioisomeric composition of LPA production. The evaluation
of this mechanism is fundamental to understanding the role the different regioisomers of
lysophospholipids play in regulation of enzymatic activity, ligand binding, and receptor
activation. These studies will require the development of a rapid lipid extraction method
preferentially shorter than the time it takes for acyl migration. Development of such
method will be subject of future investigations that are beyond the scope of the present
thesis.
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Figure 3.7 HPLC-MS/MS chromatogram of LPC 18:1 at varying time points in
plasma and serum. Lipid extractions from plasma at time 0 (panel A), serum at 1 hour
(panel B), and serum at 24 hours (panel C) were injected in
acetonitrile/methanol/isopropanol/water (1/1/1/1, V/V/V/V) solvent and methanol/water
(90/10, V/V), 5mM ammonium formate mobile phase. The ratio of the sn-1 to sn-2
regioisomers was 9:1 for all three time points.
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Figure 3.8 HPLC-MS/MS chromatogram of LPA 18:2 at varying time points in
plasma and serum. Lipid extractions from plasma at time 0 (panel A), serum at 1 hour
(panel B), and serum at 24 hours (panel C) were injected in
acetonitrile/methanol/isopropanol/water (1/1/1/1, V/V/V/V) solvent and methanol/water
(80/20, V/V), 5mM ammonium formate mobile phase.
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